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Obesity is highly prevalent in polycystic ovary syndrome (PCOS). It worsens reproductive 
and metabolic abnormalities of the syndrome, in particular insulin resistance (IR), Weight 
manegment and decreasing IR with lifestyle modification and metformin are well-addressed 
targets in this population, yet a conversion rate to prediabetes in obese women with PCOS 
remains 2-3 times higher when compared to the expected conversion rate of 1%–5% per year 
in the general obese population. 
Unmet goals imply that potential new modifiable risk factors and novel treatment strategies 
should be addressed in this metabolically high-risk population. Lately, the mounting 
evidences indicate that impairments of glucagon-like peptide 1 (GLP-1) axis have an 
important role in deregulation of appetite and glucose homeostasis. Enhancement of impaired 
GLP-1 axis by individually tailored strategies should be considered in a subset of women with 
PCOS with the highest metabolic risk and expected fast conversion rate toward diabetes. In 
the following doctoral dissetation we focused on the relationship between incrtein axis and 
metabolic disorders in obese women with PCOS and the potential impact of enhancement of 
the GLP-1 effect with dipeptidyl peptidase-4 (DPP-4) inhibitors on body weight and beta-cell 
function in the subset of women with PCOS with the highest metabolic risk. 
The first part of the disseratation consists of the case control study where the post-load GLP-1 
response in obese women with normal glucose tolerance (NGT) was compared to post load 
GLP-1 response in obese women with PCOS and prediabetes. 26 obese women with PCOS 
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phenotype A were included in the study. Thirteen of them had NGT and 13 had prediabetes 
defined as having impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or both. 
They were matched for BMI and age. Serum glucose, insulin, C-peptide, total GLP-1 and 
total glucose-dependent insulinotropic peptide (GIP) were sampled during oral glucose 
tolerance test (OGTT). Model-derived static and dynamic parameters for the assessment of 
beta-cell function and IR were determined. All patients underwent measurement of androgen 
profile and whole-body composition by a Hologic Dual Energy X-ray Absorptiometer (DXA). 
In the second and third part of the dissertation we considered the potential role of 
enhancement of endogenous GLP-1 with DPP-4 inhibitor in PCOS population 
Firstly we assessed the relevance of the intervention with DPP-4 inhibitors in metformin-
intolerant woman with PCOS and high metabolic risk. A 12-week prospective randomized 
open-label clinical study with 30 obese metformin-intolerant women with PCOS was 
conducted. After metformin withdrawal, they were randomized to lifestyle intervention and 
DPP-4 inhibitor sitagliptin (SITA) or lifestyle intervention alone as controls (CON). All 
participants underwent anthropometric, endocrine measurements and OGTT. Model-derived 
indexes of IR and beta-cell function were calculated. 
Secondly a 12-week prospective randomised open-label study was conducted to evaluate the 
effect of DPP-4 inhibitor addition to metformin therapy on body weight maintenance after 
discontinuation of treatment with GLP-1 receptor agonist liraglutide, that has been established 
as an antiobesity treatment and is often discontinuated in clinical practice due to development 
of treatment resistence. The study was conducted with 24 obese women with PCOS who had 
been pretreated with liraglutide 3.0 mg due to anti-obesity management. They were 
randomized to combined treatment (COMBO) with sitagliptin and metformin or metformin 
monotherapy (MET). Lifestyle intervention was promoted in both groups. Eating behaviour 
was assessed by a Slovenian translation of Three-Factor Eating Questionnaire (TFEQ-R18). 
In the first part we demonstrated that GLP-1 response to oral glucose load was reduced in 
obese PCOS with prediabetes, independent of age, BMI and disease phenotype, when 
compared to obese PCOS with NGT. Values of total GLP-1 at 120 min below 3.0 pM 
predicted prediabetes. Plasma GLP-1 level at 120 min was negatively correlated with visceral 
adipose tissue and positively correlated with oral glucose insulin sensitivity index. 
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Furthermore, the correlation between the ΔAUCGLP-1 and the family history of at least one 
first-degree relative affected with type 2 diabetes (T2D) was confirmed.  
It was demonstrated in the second part that enhancement of endogenous GLP-1 effect with 
DPP-4 inhibitor sitagliptin in metformin-intolerant obese PCOS lead to preservation of beta-
cell function and seemed to delay development of impaired glucose homeostasis. In addition 
to preservation of beta-cell function, treatment with sitagliptin also assisted with maintenance 
of body weight in particular due to prevention of increasing in visceral adiposity after 
metformin withdrawal. 
Beneficial effect of enhancement of endogenous incretin effect with DPP-4 inhibitor was 
demonstrated also after cessation of anti-obesity treatment with liraglutide in obese women 
with PCOS, where DPP-4 inhibitor added to metformin resulted in prevention of weight 
regain. In addition women treated with DPP-4 inhibitor sitagliptin had greater ability to resist 
emotional eating when compared to women treated with metformin monotherapy. 
Our results indicate that impaired GLP-1 response could be a new separate risk factor for 
prediabetes in PCOS independent of BMI, age and disease phenotype. We demonstrated that 
DPP-4 inhibitors are a promising therapy to prevent weight regain after cessation of anti-
obesity treatment with GLP-1 analoge liraglutide and also seem to be an alternative treatment 
in PCOS women with high metabolic risk that have failed with lifestyle intervention and are 
metformin-intolerant. 
 
Keywords: PCOS, prediabetes, GLP-1 response, DPP-4 inhibitor, sitagliptin, weight 

















Za sindrom policističnih jajčnikov (PCOS) je značilna visoka prevalenca prekomerne telesne 
mase, ki poslabšuje izraženost reproduktivnih in presnovnih zapletov PCOS, zlasti inzulinske 
rezistence (IR). Zmanjševanje telesne mase in IR s spremembo življenjskega sloga in 
metforminom je za zmanjševanje zapletov PCOS ključnega pomena. Kljub zdravljenju ostaja 
stopnja razvoja prediabetesa pri debelih ženskah s PCOS 2-3-krat večja v primerjavi s 
pričakovano 1% -5% letno stopnjo konverzije v splošni populaciji ljudi s prekomerno telesno 
maso, kar kaže na to, da je v populaciji debelih žensk s PCOS potrebno vpeljati nove 
strategije zdravljenja s targetiranjem potencialnih novih dejavnikov tveganja. 
Izsledki dosedanjih raziskav kažejo, da ima oslabljen odgovor hormonske osi glukagonu-
podobnega peptida 1 (GLP-1) pomembno vlogo pri deregulaciji apetita in glukozne 
homeostaze. Ojačanje oslabljene GLP-1 osi bi morda lahko predstavljalo individualno 
prilagojeno alternativno farmakološko strategijo v podskupini žensk s PCOS z visokim 
presnovnim tveganjem in pričakovanim hitrim razvojem prediabetesa. 
V doktorski disertaciji smo se osredotočili na potencialno vlogo oslabljenega odgovora 
inkretinske hormonske osi pri presnovnih zapletih debelih bolnic s PCOS in na vpliv z 
zaviralci dipeptidil peptidaze-4 (DPP-4) povečanega učinka GLP-1 na telesno maso in beta-
celično funkcijo pri podskupini žensk s PCOS in visokim presnovnim tveganjem. 
V prvem delu disertacije smo v presečni študiji primerjali odziv GLP-1 po oralnem glukozno 
tolerančnem testu (OGTT) pri debelih PCOS z normalno toleranco za glukozo (NGT) in 
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debelih PCOS s prediabetesom. V raziskavo smo vključili 26 debelih žensk s PCOS fenotipa 
A. Trinajst od njih je imelo NGT, 13 pa jih je imelo prediabetes, ki je bil opredeljen kot 
motena bazalna glikemija, moteno tolerance za glukozo, ali oboje. Preiskovanke se niso 
razlikovale v indeksu telesne mase (ITM) in starosti. Vse preiskovanke so opravile OGTT, 
med katerim so bili odvzeti vzorci krvi za določitev serumske glukoze, C-peptida, inzulina, 
celokupnega GLP-1 in celokupnega od glukoze odvisnega insulinotropnega polipeptida 
(GIP). Za oceno beta-celične funkcije in IR smo uporabili statične in dinamične modelne 
indekse. Vse preiskovanke so opravile merjenje sestave celega telesa s pomočjo rentgenskega 
absorptiometra Hologic Dual Energy (DXA).  
V drugem in tretjem delu disertacije smo preučili potencialno vlogo z DPP-4 zaviralci 
podaljšanega endogenega GLP-1 učinka v populaciji PCOS. 
Najprej smo ocenili smiselnost zdravljenja z DPP-4 zaviralci pri metabolno visoko ogroženih 
ženskah s PCOS, ki ne prenašajo metformina. V 12-tedensko prospektivno randomizirano 
odprto raziskavo smo vključili 30 preiskovank s PCOS in debelostjo, ki ne prenašajo 
metformina. Po prekinitvi terapije z metforminom, so bile randomizirane v skupino, ki je 
poleg promocije zdravega življenjskega sloga prejemala DPP-4 zaviralec sitagliptin (SITA), 
in kontrolno skupino (CON), ki je bila deležna promocije zdravega življenjskega sloga. Pri 
vseh preiskovankah smo opravili antropometrične in endokrinološke meritve ter OGTT. IR in 
beta-celično funkcijo smo izračunali na podlagi statičnih modelnih indeksov. 
V nadaljevanju smo z 12-tedensko randomizirano odprto klinično raziskavo želeli proučiti 
učinkovitost kombiniranega zdravljenja z DPP-4 zaviralcem in metforminom pri vzdrževanju 
telesne mase po zaključeni terapiji z agonistom GLP-1 receptorja liraglutidom. Uporaba 
liraglutida je ustaljena terapija za zdravljenje debelosti, vendar je v klinični praksi zdravljenje 
z liraglutidom po določenem času pogosto prekinjeno zaradi razvoja odpornosti na zdravljenje 
oziroma pojava neučinkovitosti pri redukciji telesne mase. V raziskavo smo vključili 24 
preiskovank s PCOS in debelostjo, ki so bile predhodno zaradi debelosti zdravljene z 
liraglutidom 3mg/dan. Po ukinitvi liraglutida so bile randomizirane v skupino, ki je prejemala 
kombinirano terapijo s sitagliptinom in metforminom (COMBO skupina) in skupino, ki je 
prejemala monoterapijo z metforminom (MET skupina). V obeh skupinah je bil promoviran 
zdrav življenjski slog. Po randomizaciji in na koncu študije so vse udeleženke opravile 
standardne antropometrične in endokrine meritve. S slovenskim prevodom trifaktorskega 
vprašalnika (TFEQ-R18) je bil ocenjen vedenjski vzorec prehranjevalnih navad  
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V prvem delu smo ugotovili, da je v primerjavi z bolnicami s PCOS in NGT, pri bolnicah s 
PCOS, ki imajo prediabetes inkretinski odgovor pomembno znižan in je neodvisen od ITM; 
starosti in fenotipa bolezni. Vrednosti GLP-1 po obremenitvi z glukozo pod 3,0 pM so 
značilne za prediabetes. Vrednost GLP-1 v 120 min OGTT je bila negativno povezana s 
količino visceralnega maščobnega tkiva ter pozitivno z oralnim indeksom občutljivosti 
glukoze na insulin. Potrjena je bila tudi negativna povezava med razliko v odgovoru GLP-1 
na glukozno obremenitev in družinsko anamnezo vsaj enega prvostopenjskega sorodnika s 
SB2. 
V drugem delu smo s podaljšanjem endogenega učinka endogenega GLP-1, ki smo ga dosegli 
z zaviralcem DPP-4 sitagliptinom pri debelih ženskah s PCOS, ki ne prenašajo metformina, 
dosegli ohranitev beta-celične funkcije in zdi se, da tudi upočasnitev razvoja motene glukozne 
homeostaze. Poleg ohranitve beta-celične funkcije je intervencija s sitagliptinom po ukinitvi 
metformina pripomogla pri vzdrževanju telesne mase, zlasti pri preprečevanju povečanja 
visceralne maščobe.  
Ugoden učinek podaljšanega endogenega inkretinskega učinka, ki smo ga dosegli z 
zaviralcem DPP-4 smo prikazali tudi pri intervenciji z zaviralcem DPP-4 po ukinitvi 
zdravljenja debelosti z liraglutidom pri debelih ženskah s PCOS, kjer smo ob kombinirani 
terapiji z zaviralcem DPP-4 in metforminom dosegli učinkovitejše preprečevanje ponovnega 
porasta telesne mase, hkrati je bila dokazana tudi večja sposobnost upiranja čustvenemu 
prehranjevanju. 
Naši rezultati nakazujejo da bi lahko oslabljen GLP-1 odziva predstavljal nov samostojen 
dejavnik tveganja za razvoj prediabetesa pri ženskah s PCOS, neodvisen od BMI, starosti in 
fenotipa bolezni. Prikazali smo, da zaviralci DPP-4 predstavljajo obetavno zdravljenje za 
preprečevanje ponovnega pridobivanja telesne mase po prenehanju zdravljenja debelosti z 
analogom GLP-1 receptorja liraglutidom. Glede na izsledke disertacije se zdi, da so zaviralci 
DPP-4 smiselno alternativno zdravljenje pri ženskah s PCOS in visokim presnovnim 
tveganjem, ki ne prenašajo metformina. 
 
Ključne besede: PCOS, prediabetes, GLP-1 odziv, DPP-4 zaviralec, sitagliptin, vzdrževanje 












INTRODUCTION AND AIMS 
 
 
Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting 15-20% women 
in reproductive age [1].Obesity is closely associated with the syndrome, presenting in about 
40–80% of patients. The risk for excess body weight in this population is up to 2.8 higher than 
in women without PCOS [2,3]. 
High prevalence of obesity exacerbates insulin resistance (IR) and metabolic risk of these 
patients [4]. Impaired glucose tolerance(IGT) and Type 2 diabetes (T2D) are present in 30-
45% in the obese PCOS patients of reproductive age [5]. High conversion rate from normal 
glucose tolerance (NGT) to prediabetes and T2D in obese women with PCOS is consequence 
of IR along with beta-cell dysfunction and decreased insulin sensitivity [6]. Reducing the rate 
of conversion to type 2 diabetes is effective with reducing the IR with lifestyle modification 
and metformin, [7] while preservation of beta-cell function remains unaddressed. In addition 
to exacerbation of IR, obesity increases the level and the biological effectiveness of 
androgens, which are critical in the pathogenesis of the syndrome. Reduction of body weight 
is therefore crucial in overweight and obese women with PCOS. Even 5-10% reduction in 
body weight significantly improves IR, increases the number of ovulations and reduces 
metabolic risk [8]. 
Regulation of appetite and energy intake is essential to maintain and reduce body mass. The 
main reason for eating beyond metabolic needs that results in obesity is an inability to control 
eating behaviour. Eating behaviour is regulated by cognitive functions and emotional inputs 
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[9,10]. It is a complex pattern based on communication between specific regulatory and 
hedonistic centres in hypothalamus and peripherial signals, including those from 
gastrointestinal tract, part of which are incretin hormones. The main incretin hormones are 
glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). GLP-1 
has direct inhibitory effect on the homeostatic and hedonic centres of appetite in the central 
nerves system and indirect inhibitory effect via delaying gastric emptying rates and slowing 
gastrointestinal tract motility, which result in decreased food intake and consequently in body 
weight reduction [9,11]. In contrast to GLP-1, no effect on appetite and body weight is shown 
with GIP [12]. Incretin hormones have a short half-life. They are rapidly inactivated by the 
enzyme dipeptidyl peptidase-4 (DPP-4) enzyme. 
Beside the GLP-1 role in energy balance, both incretin hormones are involved in glucose 
homeostasis [12]. They are secreted from endocrine cells in the small intestine under the 
influence of food intake and are responsible for 50-70% of postprandial insulin secretion. This 
is so-called incretin effect and is proportional to the current glycaemia [9,12]. Obesity with 
the onset of IR and consequent metabolic diseases, such as impaired glucose tolerance and 
T2D, impairs the effect of incretins. Postprandial GLP-1 concentration in obese people is 
lower than in people with normal body weight [13-16]. Similarly, lower postprandial GLP-1 
values were measured in patients with T2D, while the GIP response in this population was 
preserved [17-21]. 
In PCOS impaired glucose homeostasis is closely linked to obesity, age and 
disease phenotype. The potential separate role of reduced incretin response in the 
development of prediabetes and diabetes in this population is unclear [22-28]. 
Recent clinical practice guidelines recommend lifestyle modification as the first line 
intervention in obese PCOS [29]. Low glucose index diet and hypocaloric diet leads to 
decrease in body mass index (BMI), waist circumference, and waist to hip ratio [30]. 
Modification of lifestyle is associated with an important improvement of hormonal [31-33] 
and metabolic abnormalities such as a decrease in serum insulin and fasting glucose levels, an 
improvement in IR and decline in diastolic blood pressure [31-33]. Lifestyle changes also lead 
to improvement of fertility function [30,34,35]. However, the treatment goals with lifestyle 
intervention are usually hardly achievable and non-sustainable in everyday life. 
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Metformin is considered as a first line pharmacological therapy in obese PCOS with high 
metabolic risk [36]. It reduces IR and is undoubtedly effective in reducing the rate of 
conversion to T2D [7]. In addition, several studies have suggested a positive effect on 
menstrual irregularities, irrespective of pretreatment presence of IR or weight [37-39]. 
Its long-term safety profile is favorable, but up to 25% of patients suffer metformin-associated 
gastrointestinal effects [40] that could have a deleterious effect on quality of life and result in 
high rates of nonadherence [41]. Tolerance is affected by genetic variation in intestinal 
transporters of metformin, the production of lactate concentrations within enterocytes, 
increases in GLP-1 concentrations, bile acid pool, and altered microbiome [42]. Strategies to 
lessen the adverse events include appropriate titration of immediate-release metformin and 
use of extended-release metformin and gut-microbiome modulators. However, approximately 
5-10% of patients are still unable to tolerate metformin at all [40,43]. The alternative 
pharmacological strategy to reduce metabolic risk when metformin cannot be tolerated is not 
established in this population. Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) inhibit the 
enzyme DPP-4, which otherwise inactivates the incretin hormones. They promote extended 
endogenous incretin effect and lead to improvement in metabolic control as well as the 
reduction of metabolic risks [44]. DPP-4 inhibitors might represent an alternative 
pharmacological intervention in patients with PCOS and high metabolic risk, when therapy 
with metformin is not tolerated at all. Research in this area is currently lacking. 
When addressing weight loss with metformin therapy, the best documented absolute weight 
reduction, was in obese rather than in lean women with PCOS, had been about 2.7 kg, 
representing less than 5% of weight reduction [45,46]. No benefit regarding weight reduction 
was recognized when metformin was added on lifestyle changes. In a small study with 19 lean 
and 21 obese PCOS the impact of metformin on incretin hormones was demonstrated with the 
increase of GLP-1 during OGTT with 8 month metformin intervention [24]. 
Recently, glucagon-like peptide 1 receptor agonist (GLP-1 RA) liraglutide became an 
established antiobesity therapy [47]. In composite data analysis of the landmark SCALE 
trials, 3 mg liraglutide led to 7.5% weight loss over 1 year compared with 2.3% for placebo. 
Its effect on body weight appears to be due to influence on central and peripherial 
mechanisms of appetite regulation [48]. Stimulation of mesolimbic GLP-1 receptor is 
sufficient to reduce hunger-driven feeding and the hedonic value of food [49]. Liraglutide 
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treatment was also shown to be associated with weight loss and improved eating behaviour in 
some recent small studies in PCOS [50-54]. 
The most reasonable duration of weight management with liraglutide is not yet defined. The 
FDA (Food and Drug Administration) recommends that liraglutide 3 mg is discontinued after 
16 weeks if the subject has not lost at least 4% of baseline body weight [55]. The EMA 
(European Medicines Agency) recommends its discontinuation if 5% weight loss have not 
been achieved after 12 weeks at the dose of 3 mg [56]. When guideline thresholds for efficacy 
are met, liraglutide could sustain weight loss over 2 years and improve many of the important 
obesity-associated metabolic and cardiovascular risk factors with no major safety issues [47]. 
However, after treatment withdrawal, weight loss achieved with liraglutide is often non-
sustainable [57]. The clinical strategy to prevent the rebound of weight gain in subjects that 
have been withdrawn from liraglutide is not yet elucidated.  
With respect to body weight, DPP-4 inhibitors are generally described as being weight 
neutral, although modest weight reduction has been seen in some clinical trials, particularly 
when DPP-4 inhibitors are used in combination with metformin [58,59]. Nevertheless, the 
mere fact that DPP-4 inhibition is not associated with the weight gain that typically 
accompanies improved glycemic control in patients with T2D does suggest that DPP-4 
inhibitors may not be completely neutral in this respect [60]. Slowing of gastric empting that 
might reinforce the sustained beneficial change of eating behaviour was demonstrated with 
treatment with DPP-4 inhibitor sitagliptin [61]. 
The clinical strategy to prevent the rebound of weight gain in subjects that have been 
withdrawn from liraglutide is not yet elucidated. 
To our knowledge, the thesis is the first investigation into 
1) the role of incretin axis in the development of prediabetes;  
2) the role of enhanced endogenous incretin effect with DPP-4 inhibitors in metformin 
intolerant obese PCOS and  
3) the role of DPP-4 inhibitors in potential prevention of rebound weight gain in patients 
that have been withdrawn from liraglutide.  
5 
 
Aims and hypotheses 
The aim of doctoral thesis was to study the difference in GLP-1 response after OGTT in obese 
PCOS women with normal glucose tolerance and obese PCOS with prediabetes, and to 
evaluate the influence of extended endogenous incretin effect, promoted with DPP-4 
inhibitors, on beta-cell function in metformin intolerant women and on weight maintenance 
after liraglutide cessation.  
The thesis is divided into three self-standing studies that are designed to form related unit 
describing important new insights into the role and impact of the incrtein system and the DPP-
4 inhibitors on body weight and beta-cell function in obese women with PCOS. 
 
1. The first part consists of case control study where the GLP-1 response after OGTT in a 
cohort of obese PCOS with NGT and prediabetes has been compared.  
It was hypothesized that obese women with PCOS and impaired glucose homeostasis have 
reduced incretin effect in comparison with obese woman with PCOS and normal glucose 
homeostasis. 
 
2. The second part consists of prospective randomized open-label clinical study of 12 week 
duration and considered the relevance of the intervention with DPP-4 inhibitors in metformin 
intolerant woman with PCOS and high metabolic risk.  
It was hypothesized that DPP-4 inhibitors have beneficial effect on beta-cell function in 
metformin intolerant patients with PCOS and high metabolic risk. 
 
3. The third part of thesis consists of a 12-week prospective randomised open-label study 
aiming to evaluate the effect of DPP-4 inhibitor addition to metformin therapy on body 
weight maintenance after discontinuation of antiobesity treatment with liraglutide.  
It was hypothesized that after liraglutide withdrawal combined treatment with DPP-4 inhibitor 
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IMPAIRED GLP-1 RESPONSE PREDICTS 
PREDIABETES IN OBESE PCOS WITH ADVERSE 










Impaired glucose homeostasis in PCOS is most closely linked to obesity, age and disease 
phenotype [62]. BMI more than 30 kg/m2, age more than 30 years and irregular menstrual 
cycles with the concomitant presence of hyperandogenism and PCO morphology as classified 
by a disease phenotype A, are the strongest risk factors associated with adverse metabolic 
profile in PCOS population [63,64]. Conventionally, BMI is considered as the only 
modifiable risk factor. First line treatment strategies in obese PCOS with high metabolic risk 
are therefore focused on weight management [36,65]. Despite the established strategies, a 
conversion rate to prediabetes in obese women with PCOS remains 2-3 times higher when 
compared to the expected conversion rate of 1%–5% per year in the general obese population 
[66]. 
Potential new modifiable risk factors should be addressed in this metabolically high-risk 
population. Lately, the mounting evidences indicate that incretin hormone GLP-1 has an 
important role for maintaining normal glucose regulation, yet the reports about its impact on 
metabolic derangements in different cohorts are still diverse and controversial [13-
16,19,20,67,68]. Few studies tried to identify PCOS as an independent risk factor for impaired 
GLP-1 response with inconclusive results. PCOS was related either with similar or decreased 
or increased fasting and lower postprandial levels of GLP-1[22-28]. Also studies concerning 
the BMI as an independent risk factor for the impairment of GLP-1 in PCOS were diverse. 
Some studies demonstrated no difference in GLP-1 response between lean and obese PCOS, 
whereas others reported lower levels of GLP-1 in obese compered to lean women [26,28]. 
The potential separate role of incretin axis in the development of prediabetes in PCOS 
remains unclear. The aim of the study was to compare GLP-1 response after OGTT in obese 
PCOS women with NGT to GLP-1 response in obese PCOS with prediabetes. 
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SUBJECT AND METHODS 
 
 
Study design and participants 
A case control study recruited 26 obese Caucasian women with PCOS. Eligible patients were 
required to have phenotype A with the concomitant presence of irregular periods with cycle 
length outside 21–35 days or fewer than eight cycles per year, biochemical or clinical 
evidence of hyperandrogenism and PCO morphology. All of them had normal serum prolactin 
concentrations and thyroid function tests. Possible Cushing’s syndrome was excluded when 
clinically indicated. When basic 17α-hydroxy-progesterone was > 6.1 nmol/L (2 ng/ml) the 
determination of 17α-hydroxy-progesterone after stimulation with Synacthen test was 
performed to rule out non-classic congenital adrenal hyperplasia. Thirteen of them had NGT 
and 13 had prediabetes defined as having impaired fasting glucose (IFG), impaired glucose 
tolerance (IGT) or both [69]. They were matched for BMI (37.8±6.9kg/m2, and 
36.2±3.8kg/m2, mean ± SD for NGT and prediabetes respectively, p=0.579) and age 
(37.1±7.3 and 37.4±6.7 years mean ± SD for NGT and prediabetes respectively, p=0.920). 
Serum glucose, insulin, C-peptide, total GLP-1 and total GIP were sampled during 3h-OGTT. 
Lipid profile was measured. Model derived static and dynamic parameters for the assessment 
of beta-cell function and IR were determined. All patients underwent measurement of 
androgen profile and whole-body composition by a Hologic Dual Energy X-ray 
Absorptiometer (DXA). The study protocol is shown in Scheme 1. 
The study was approved by the Slovene National Medical Ethics Committee and conducted in 
accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Written 
informed consent was obtained from all patients before participation. The study is registered 
at www.ClinicalTrials.gov as NCT03325569. 
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Glucose levels were determined using a standard glucose oxidase method (Beckman Coulter 
Glucose Analyzer, Beckman Coulter Inc CA, USA). Insulin was determined by 
immunoradiometric assay (Biosource Europe S.A., Nivelles, Belgium). C-peptide was 
measured using an immunoenzymometric method based on specific monoclonal antibodies. 
Total GLP-1 levels were measured in plasma using commercially available kit Total GLP-1 
ELISA (7-36 and 9-36) (Alpco, Catalog no. 43-GPTHU-E01), according to the 
manufacturer’s instructions. Standards, controls and samples were added in duplicates to the 
designated wells of the streptavidin coated microplate, followed by total GLP-1 tracer 
antibody and total GLP-1 capture antibody mixture. The plate was covered and incubated for 
20-24 hours at 2-8 OC. On the next day, the plate was washed and substrate was added into 
each well. The plate was incubated in the dark for 20 minutes at room temperature. Stop 
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solution was added and the absorbance was read at 450nm/620nm within 10 minutes, using 
Tecan Safire (Tecan Group Ltd., Switzerland). 
Total GIP levels were measured using Human GIP (Total) ELISA kit (EZHGIP-54K, EMD 
Millipore, USA), according to the manufacturer’s instructions. Briefly, assay buffer was 
added to the microplate, coated with anti-GIP monoclonal antibodies, followed by the matrix 
solution to the blank, standard and control wells. Standards, controls and samples were added 
to the designated wells in duplicates. The plate was incubated for 1.5 hours at room 
temperature. After washing, the detection antibodies were added to all the wells and the plate 
was incubated for 1 hour at room temperature, followed by washing, addition of enzyme 
solution, and subsequent 30 minutes incubation. The plate was washed and substrate solution 
was added for 20 minutes, after which the reaction was stopped and absorbance was read at 
450nm/590nm within 5 minutes, using Tecan Safire (Tecan Group Ltd., Switzerland).  
Lipids were determined using Adiva 1800, Siemens analyzer.  
Sex hormone binding globulin (SHBG) was determined with a chemiluminescent 
immunoassay (Immulite 2000 Analyzer, Siemens Healthcare, Erlangen, Germany). 
Total and free testosterone levels were measured by coated tube RIA (DiaSorin, S. p. A, 
Salluggia, Italy and Diagnostic Products Corporation, LA, respectively).Androstenedione and 
DHEAS were measured by specific double antibody RIA using 125 I-labeled hormones 
(Diagnostic Systems Laboratories, Webster, Tx).  
 
Assessment of human body composition by Dual Energy X-ray 
Absorptiometry  
Whole-body composition was assessed by a DXA (Discovery A; Hologic, Waltham, MA, 
USA) with the software provided by the manufacturer (QDR for Windows Version 12.5). 
 
Calculations: 




To assess beta-cell function basic insulin secretion function index (HOMA-B), modified beta- 
cell function index (MBCI) [70] and quantitative insulin sensitivity check index (QUICKI) 
[71] was calculated.To assess insulin sensitivity from the OGTT, oral glucose insulin 
sensitivity (OGIS) index was used.  
As a measure of IR homeostasis model assessment (HOMA-IR) calculation [72] and insulin 
action index (IAI) was applied [70]. 
The respective formulas for calculating the above mentioned parameters were as follows: 
HOMA-B = 20× I0/(G0-3.5), MBCI = I0×G0/(G120+G60-7), QUICKI = 1/[log(I0) + log(G0)]), 
HOMA-IR=I0× G0/22.5 and IAI = 1 /(I0×G0) wherein I0 (mU/L) denotes fasting plasma 
insulin, G0 (mmol/L) fasting plasma glucose, G60 (mmol/L) plasma glucose level at 60 
minutes after glucose load, and G120 (mmol/L) plasma glucose level at 120 minutes after 
glucose load in OGTT test.  
OGIS index was calculated using the internet calculator available at: http //webmet.pd.cnr.it / 
OGIS / index.php 
 
Statistical analysis: 
Patients’ clinical characteristics were presented as mean values with standard deviations. 
Nonparametric Mann-Whitney test was used to compare continuous variables between 
different patient groups, while Spearman’s rho was used to assess correlations between 
different continuous variables. To determine the area under the curve, as well as sensitivity 
and specificity, ROC curve analysis was used. Cut-off value was determined as the value with 
the highest sum of sensitivity and specificity. Two tailed P values of <0.05 were considered 
statistically significant. All statistical analyses were performed using IBM SPSS Statistics 







The characteristic of the patients with prediabetes and NGT are provided in Table 1.1 There 
were no statistically significant differences in weight, BMI, age, waist circumference, baseline 
hormonal status, cholesterol and triglyceride levels between both groups. 
 
Incretin hormones 
Baseline plasma GLP-1 concentration did not differ between groups (p=0.169). In both 
groups GLP-1 concentrations rose after glucose load (change in GLP-1 level during OGTT 
was 0.4±1.4 in NGT and 0.2±1.0 in prediabetes group; p=0.579).Women with prediabetes had 
significantly lower total GLP-1 after glucose load (GLP-1 in 120 min 3.3±2.1 vs. 5.5±2.7 pM 
in NGT, p=0.014).  
According to ROC curve analysis, lower values of GLP-1 at 120 min of OGTT were 
associated with higher probability of IGT/IFG (AUC=0.781 (0.600-0.962), p=0.015) with cut-
off value 3.0 pM (sensitivity 0.615 and specificity 0.923) (Figure 1.1). 
GIP concentration did not differ between groups at base line (81.3±25.2 pg/ml and 80±56.2 
pg/ml for prediabetes and group with normal glucose tolerance, respectively (p=0.243)). After 
glucose load GIP levels increased without significant between group difference (p=0.614). 
 
Parameters of static and OGTT related measures of glycemic control 
Baseline plasma insulin levels were higher in prediabetes group, but between group difference 
was not significant. After glucose load insulin levels increased in both groups. At 60 min level 
of insulin tended to be higher in prediabetes group, but the difference was not statistically 
significant, while insulin levels obtained at 90, 120 and 180 min during OGTT were 
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significantly higher in prediabetes group (p< 0.05 for all). In both groups peak levels of 
plasma insulin were reached at 60 min of OGTT (Table 1.1). 
Insulin sensitivity index (OGIS) was significantly lower in prediabetesgroup (326.6±59.7 
ml/min m2 vs. 387±69.5ml/min m2 in NGT; p=0.044), along with worse static measures of 
beta-cell function, assessed by HOMA-B, MBCI and QUICKI, although the between group 
differences in static measures of beta-cell function were not statistically significant (Table 
1.1). 
HOMA-IR and IAI was higher in prediabetes group but between group differences were not 
statistically significant.  
 
Measures of obesity 
Despite no between group difference in BMI and waist circumference, women with 
prediabetes had higher visceral adipose tissue (VAT) mass, volume and area as measured by 
DXA (p=0.001 for all, Table 1.1).  
 
Correlations  
In the total study population higher plasma GLP-1 levels at 120 min of OGTT were 
significantly related to higher OGIS (Spearman’s rho r= 0.424, p=0.031). Patients with higher 
plasma GLP-1 tended to have lower VAT mass (Spearman’s rho r=-0.388, p=0.055), VAT 
volume (Spearman’s rho r=-0.390, p=0.054) and VAT area (Spearman’s rho r= -0.381, 
p=0.060). In addition, the correlation between the change in GLP-1 during OGTT and the 





Table 1.1: Comparison of clinical characteristics of patients with NGT or IGT/IFG using 
Mann-Whitney test 





Age (years) 37.1±7.3 37.4±6.7 0.920 
Weight (kg) 103.3±14.2 99.2±9.2 0.650 
BMI (kg/m2) 37.8±6.9 36.2±3.8 0.579 
Waist circumference (cm) 101.5±12.7 107.5±10.7 0.223 
Glu 0 min OGTT (mmol/l) 5.3±0.4 6.3±1 0.002 
Glu 30 min OGTT (mmol/l) 7.6±1.4 10.7±2.4 <0.001 
Glu 60 min OGTT (mmol/l) 7.3±2.1 12±4 <0.001 
Glu 90 min OGTT (mmol/l) 6.9±1.2 11.4±3.8 <0.001 
Glu 120 min OGTT (mmol/l) 6.3±1.1 10±2.8 <0.001 
Glu 180 min OGTT (mmol/l) 4.6±0.7 6.1±1.9 0.044 
Insulin 0 min OGTT (mU/l) 12.3±8.3 15±7.4 0.336 
Insulin 30 min OGTT (mU/l) 91.8±55.5 88.4±59.8 0.687 
Insulin 60 min OGTT (mU/l) 92±70.2 114.7±59.6 0.204 
Insulin 90 min OGTT (mU/l) 77.8±59.4 109.5±50.7 0.016 
Insulin 120 min OGTT (mU/l) 72.2±51.7 110.4±44.9 0.016 
Insulin 180 min OGTT (mU/l) 37.2±49.8 54.5±31.5 0.022 
C-peptide 0 min OGTT (pmol/l) 0.8±0.3 1.2±0.4 0.010 
C-peptide 30 min OGTT (pmol/l) 3.2±1.1 3.2±1.2 1.000 
C-peptide 60 min OGTT (pmol/l 3.7±1.3 4.4±1.1 0.113 
C-peptide 90 min OGTT (pmol/l) 3.4±1.2 4.7±0.9 0.001 
C-peptide 120 min OGTT (pmol/l) 3.3±1 4.6±0.9 0.005 
C-peptide 180 min OGTT (pmol/l) 1.8±1.3 2.9±1.4 0.029 
GLP-1 0 min (pM) 5.2±3.2 3.1±1.5 0.169 
GLP-1 120 min (pM) 5.5±2.7 3.3±2.1 0.014 
GIP 0 min (pg/ml) 80±56.2 81.2±25.2 0.243 
GIP 120 min (pg/ml) 229.1±88.7 257.1±99.9 0.614 
HOMA B score 148.3±111.6 115.5±57.2 0.687 
MBCI 9.8±4.7 7.5±5.2 0.153 
QUICKI 0.34±0.04 0.32±0.03 0.113 
OGIS(ml/min m2) 387±69.5 326.6±59.7 0.044 
IAI 0.02±0.02 0.01±0.01 0.113 
HOMA IR score 2.8±1.9 4.3±2.4 0.113 
Cholesterol (mmol/l) 4.9±0.9 4.9±1 0.960 
HDL (mmol/l) 1.3±0.3 1.2±0.3 0.687 
LDL (mmol/l) 3±0.8 3.1±0.8 0.960 
TAG (mmol/l) 1.5±1.1 1.9±1.4 0.336 
SHBG (nmol/l) 26.1±9.6  21.7±8.4  0.288 
Free testosterone (pmol/l) 5±3.4 6.7±2.8 0.064 
Total testosterone (nmol/l) 2±1.8 1.3±0.8 0.479 
Androstenedione (nmol/l) 7.1±8.1 4.5±2.1  0.347 
DHEAS (μmol/l) 6.7±5 5.3±2.3 0.650 
DXA %fat 44.9±6.8 45.8±2.9 0.960 
VAT mass (g) 675.3±221.4 1013.6±195.1 0.001 
VAT volume (cm3) 730.1±239.3 1098.3±211.7 0.001 
VAT area (cm2) 140.1±45.9  210.2±40.4 0.001 
Abbreviations: NGT, normal glucose tolerance; IGT, Impaired glucose tolerance; IFG, impaired fasting 
glucose; BMI, body mass index; Glu, glucose; OGTT, oral glucose tolerance test; GLP-1 glucagon-like peptide-
1; GIP glucose-dependent insulinotropic peptide; HOMA-B, homeostasis model assessment for beta-cell 
function; MBCI, modified beta-cell function index; QUICKI, quantitative insulin sensitivity check index; OGIS, 
oral glucose insulin sensitivity, IAI, insulin action index; HOMA-IR, homeostasis model assessment of insulin 
resistance; SHBG, sex hormone-binding globulin, DHEAS dehydroepiandrosterone sulphate; ACTH, 
adrenocorticotropic hormone; DXA Dual Energy X-ray Absorptiometer; VAT visceral adipose tissue;  
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Figure 1.1: ROC curve for GLP-1 at 120 min predicting prediabetes.  
 
Lower values of GLP-1 were associated higher probability of prediabetes. Cutoff (biggest 
sum of sensitivity and specificity) value of GLP-1 at 120 min is 3.02 pM 







GLP-1 response to oral glucose was reduced in obese PCOS with prediabetes independent of 
age, BMI and disease phenotype when compared to obese PCOS with NGT.Values of GLP-1 
at 120 min below 3.0 pM predicted prediabetes. Plasma GLP-1 level at 120 min was 
negatively correlated with visceral adipose tissue and positively correlated with OGIS. 
Furthermore, the correlation between the ΔAUCGLP-1 and the family history of at least one 
first-degree relative affected with T2D was confirmed. 
The sequence of cause and effect regarding relationship between glucose tolerance status and 
GLP-1 response remains uncertain. It is still controversial whether and to what extend 
reduced GLP-1 release proceeds development of T2D. In our study, we detected the reduction 
in GLP-1 response in obese PCOS women with prediabetes that preceded the development of 
T2D, independently of BMI. We identified low postload levels of GLP-1 as a separate risk for 
prediabetes in this population. Contrary to our results, some studies demonstrated that 
impaired GLP-1 release is a phenomenon secondary to type 2 diabetes, [68,73] whereas in 
agreement with our findings, other studies reported of reduced GLP-1 release even in 
individuals with prediabetes [20,67,74-76]. In a large study population of Danish adults the 
GLP-1 response to an OGTT was up to 25% impaired in prediabetes and screen detected 
diabetes compared with NGT. Impairment was more pronounced in women compared with 
men [67]. 
In addition to different glucose tolerance state, obesity has been identified as independent and 
additive predictor of an impaired GLP-1 response [16]. An inverse association between BMI 
and GLP-1 response was proven in several studies [16,20,77-79]. It was indicated that 
independent of glucose tolerance status, obese and overweight individuals had up to 20% 
impaired GLP-1 response compared with normal weight individuals. Furthermore, an increase 
in GLP-1 secretion following weight loss has been reported [79]. In our study, women with 
prediabetes and NGT had different GLP-1 response despite comparable BMI, yet prediabetes 
group had higher visceral adipose tissue as measured by DXA when compared to women with 
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NGT. We demonstrated that post load GLP-1 levels were negatively correlated with visceral 
adipose tissue independent of BMI. 
Our results indicate that the crosstalk between adipose tissue and incretin system could be 
specifically related to different adipose tissue compartments. Recently, it was recognized by 
diverse proteomic profiling of abundant adipocyte secretome, that DPP-4 is a novel adipokine 
from adipose tissue, in particular from visceral adipose tissue [80]. Knowing that DPP-4 
cleaves and inactivated the GLP-1, the observed correlation between GLP response and 
visceral adipose tissue implicate that the reduced GLP-1 response at least partly reflected an 
increased elimination of GLP-1 in addition to more likely impaired release of GLP-1. 
In addition, we showed that post load GLP-1 levels were positively related to insulin 
sensitivity index (OGIS) that was significantly higher in group with NGT when compared to 
prediabtes. These findings are in agreement with the glucoregulatory effects of GLP-1 
[81,82]. GLP-1 is an insulin secretagogue and the defective response of beta-cell to GLP-1 
may arise from decreased concentration of a given GLP-1. In addition, defective beta-cell 
responsiveness to the GLP-1 and partial inability of beta-cells to secrete insulin in response to 
stimulation might contribute to pathogenic link between incretin signalling and impaired 
glucose homeostasis [83]. 
Furthermore, we confirmed the correlation between change in participant’s GLP-1 level 
during 120 min of OGTT and the family burden of type 2 diabetes. Some of the mechanisms 
behind the different GLP-1 response in our cohort may include genetic variation in the 
regulation of GLP-1 synthesis that had also been observed in some other studies 
[19,79,84,85]. Twin studies have shown that GLP-1 response has a heritability of up to 67% 
[79]. The correlation between history of T2D in a first-degree relative and a greater 
prevalence of insulin secretory defects in a subset of PCOS that would develop either IGT or 
T2D by 30 years of age has also been reported previously [86]. 
The main strength of our study is that study population of women matched by age, BMI and 
disease phenotype was very homogenous. The majority of other studies that had been 
addressing this issue were performed in groups with different distribution of sex, age, and 
BMI. The inconsistency and inconclusiveness related to the timing and the extent of impaired 
GLP-1 response in relation with the progression to T2D and obesity could be partly 
contributed to this heterogeneity. The other strength was an early impairment of glucose 
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homoeostasis in the observed population that excluded the differences due to varying duration 
and severity of impaired glucose homeostasis and to exclude the impact of long-term use of 
drugs such as metformin or DPP-4 inhibitors that could have disturbed the natural pattern of 
GLP-1 release. 
The major limitation of our study was small sample size partly at the expanse of homogeneity. 
Future larger and prospective designs should be powered using our preliminary results.In 
addition, the GLP-1 response to OGTT may be considered less relevant than mixed meal test. 
However, mixed meal test is more difficult to standardize than an OGTT and the response 














DPP-4 INHIBITOR SITAGLIPTIN AS A POTENTIAL 
TREATMENT OPTION IN METFORMIN-










One of the major clinical problems that appear in metformin-intolerant PCOS subjects is how 
to reduce the progression rate of NGT to IGT and in turn T2D. The progression rate in 
metabolically unfavorable phenotypes of PCOS may be as high as 5 to 15% within 3 years 
[35,88]. BMI, visceral adiposity, and weight gain were found as strong predictors of 
progression in glucose derangements. In addition, IR and beta-cell dysfunction were also 
recognized as underlying important risk factors for the development of T2D in PCOS [89]. 
Few studies have addressed preservation of beta-cell function as a potential treatment target in 
this population [90,91]. 
DPP-4 inhibitors can halt or reverse the loss of functional beta-cell mass in animal models and 
may delay transition to prediabetes and T2D [92-94]. DPP-4 inhibition as an alternative 
therapeutic option has been proposed but as yet is untested in metformin-intolerant women 
with PCOS. The present study is the first investigation into the role of DPP-4 inhibitors in 
metformin-intolerant obese PCOS. The aim was to evaluate whether the DPP-4 inhibitor 
sitagliptin in combination with lifestyle intervention preserves beta-cell function in this 
population. The secondary outcomes were changes in other measures of glycemic control, 
including conversion rates to IGT and T2D, changes in hormonal parameters, anthropometric 








We conducted a 12-week, prospective, randomized, open-label study with 30 obese women 
with PCOS aged 35.0 ± 7.2 years with a BMI of 36.9 ± 5.5 kg/m2 who had been intolerant to 
metformin. Before they were defined as metformin intolerant, they were on metformin up to 8 
weeks. Metformin intolerance was defined by the presence of intolerable gastrointestinal 
adverse events encountered with metformin before randomization, including diarrhea, nausea, 
flatulence, indigestion, vomiting, and abdominal discomfort. After metformin intolerance was 
reported by the patients, the washout period before randomization was from 1 to 2 weeks.  
All included subjects fulfilled Rotterdam criteria with a metabolically unfavorable type A 
phenotype of PCOS, including concomitant presence of a) hyperandrogenemia on either the 
biochemical or the clinical level, b) menses abnormalities, and c) polycystic ovary 
morphology [95]. They were eligible for enrollment if they were aged 18 years to menopause 
and obese (BMI ≥30 kg/m2). Exclusion criteria were significant kidney or hepatic disease, 
acute and chronic pancreatitis, or known history of pancreatitis or gallbladder disease. 
Pregnancy was excluded by measuring beta-human chorionic gonadotropin. 
At the beginning of the study, lifestyle intervention was reinforced in all subjects. They 
received individual counseling regarding lifestyle intervention. A diet involving a 500 to 800 
kcal/day reduction was instituted, consisting of 50% carbohydrates, preferably with low 
glycemic index, 20% proteins, and 30% fat, mostly mono- and polyunsaturated, with the 
amount of saturated fat less than 10%. The participants were encouraged to increase 
consumption of fiber, whole grains, cereals, fruits, and vegetables along with at least 30 
minutes of moderate-intensity physical activity daily. Type of physical activity was chosen on 
the basis of ability and compliance for the individual patient; most performed walking or 
cycling. 
All participants were asked to record all food eaten and physical activity daily and to self-
report their compliance in the fourth and eighth weeks of the study, when they were seen in 
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person or contacted by phone. They had additional counseling via phone in order to promote 
adherence to the diet and exercise when needed. 
Women were randomized to lifestyle intervention and sitagliptin (SITA) or lifestyle 
intervention alone as controls (CON). Postrandomization and at the end of the study, all 
participants underwent standard anthropometric measurements: height, weight, and waist 
circumference. Assessment of whole-body composition was measured by Hologic dual-
energy X-ray absorptiometry (DXA), including visceral adipose tissue (VAT) area. A fasting 
blood sample was drawn for determination of glucose, insulin, C-peptide, total GLP-1, GIP, 
total and free testosterone, androstenedione, dehydroepiandrosterone sulfate (DHEAS), and 
sex hormone–binding globulin (SHBG), followed by a 2-hour OGTT. Blood samples for 
glucose were drawn at 0, 60, and 120 minutes in the OGTT. According to American Diabetes 
Association guidelines, OGTT was used to screen for IGT and T2D [96]. History of menstrual 
pattern was recorded. Safety clinical assessment was performed at the beginning and at the 
end of the treatment period. Lifestyle intervention was monitored and supported by offering 
individual consultations at baseline and at the fourth and eighth weeks of the study. The study 
protocol is shown in Scheme 2 
The study was approved by the Slovene National Medical Ethics Committee and conducted in 
accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Written 
informed consent was obtained from all patients before participation. The study is registered 










Glucose levels were determined using a standard glucose oxidase method (Beckman Coulter 
glucose analyzer, Beckman Coulter Inc, CA). Insulin was determined by immunoradiometric 
assay (Biosource Europe S.A., Nivelles, Belgium). C-peptide was measured using an 
immunoenzymometric method based on specific monoclonal antibodies.  
Total GLP-1 levels were measured in plasma using a commercially available kit, total GLP-1 
ELISA (7-36 and 9-36) (Alpco, catalog number 43-GPTHU-E01), according to the 
manufacturer’s instructions. Briefly, standards, controls, and samples were added in duplicate 
to the designated wells of the streptavidin-coated microplate, followed by total GLP-1 tracer 
antibody and total GLP-1 capture antibody mixture. The plate was covered and incubated for 
20 to 24 hours at 2 to 8°C. On the next day, the plate was washed and substrate was added 
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into each well. The plate was incubated in the dark for 20 minutes at room temperature. Stop 
solution was added, and the absorbance was read at 450 nm/620 nm within 10 minutes, using 
a Tecan Safire microplate reader (Tecan Group Ltd, Switzerland). 
Total GIP levels were measured using a human GIP (Total) ELISA kit (EZHGIP-54K, EMD 
Millipore, USA), according to the manufacturer’s instructions. Briefly, assay buffer was 
added to a microplate coated with anti-GIP monoclonal antibodies, followed by addition of 
the matrix solution to the blank, standard, and control wells. Standards, controls, and samples 
were added to the designated wells in duplicate. The plate was incubated for 1.5 hours at 
room temperature. After washing, detection antibodies were added to all wells, and the plate 
was incubated for 1 hour at room temperature, followed by washing, addition of enzyme 
solution, and a subsequent 30-minute incubation. The plate was washed, and substrate 
solution was added for 20 minutes, after which the reaction was stopped and absorbance was 
read at 450 nm/590 nm within 5 minutes, using a Tecan Safire microplate reader (Tecan 
Group Ltd).  
Total and free testosterone levels were measured by coated tube radioimmunoassay 
(DiaSorin, S.p.A., Salluggia, Italy and Diagnostic Products Corporation, Lousiana, 
respectively). Androstenedione and DHEAS were measured by specific double-antibody 
radioimmunoassay using 125I-labeled hormones (Diagnostic Systems Laboratories, Webster, 
TX). SHBG was determined with a chemiluminescent immunoassay (Immulite 2000 
Analyzer, Siemens Healthcare, Erlangen, Germany). 
For all tests, pre- and posttreatment samples from each patient were assayed in the same assay 
run. 
 
Assessment of body composition by DXA 
Whole-body composition was assessed by DXA (Discovery A; Hologic, Waltham, MA) using 




Calculations for the assessement of beta-cell function and IR  
To assess beta-cell function, the basic insulin secretion function index homeostasis model 
assessment for beta-cell function (HOMA-B), modified beta-cell function index (MBCI), [70] 
and quantitative insulin sensitivity check index (QUICKI) [71] were calculated. 
As a measure of IR, homeostasis model assessment of IR (HOMA-IR) [72] and insulin action 
index (IAI) were applied [70]. 
The respective formulas for calculating the above-mentioned parameters were as follows: 
HOMA-B = 20 × I0/(G0 − 3.5); MBCI = I0 × G0/(G120 + G60 − 7); QUICKI = 1/(log[I0] + 
log[G0]); HOMA-IR = I0 × G0/22.5; and IAI = 1/(I0 × G0), where I0 (mU/L) denotes fasting 
plasma insulin, G0 (mmol/L) fasting plasma glucose, G60 (mmol/L) plasma glucose at 60 
minutes after glucose load, and G120 (mmol/L) plasma glucose at 120 minutes after glucose 
load in the OGTT. 
 
Statistical analysis 
Sample size was determined based on data for mean change of HOMA-B from previous 
studies with comparative treatment intervention using Power and Sample Size Calculation, 
version 3.0.43 To detect a statistically significant difference of approximately 65 in change in 
HOMA-B between groups with 80% power (α =0.05), each group had to consist of 14 
patients. 
Mean values with standard deviations were used to describe continuous variables. To compare 
pretreatment and posttreatment values of continuous variables, we used the nonparametric 
Wilcoxon signed-rank test for related samples, whereas the nonparametric Mann-Whitney test 
was used to compare changes in clinical parameters among different treatment groups. Two-
tailed p values of <0.05 were considered statistically significant. All statistical analyses were 







The study enrolled 30 participants. Two patients in CON discontinued the study because of 
protocol violation. Fifteen women in SITA and 13 in CON completed the study. Baseline 
characteristics of the patients are provided in Table 2.1. There were no statistically significant 
differences between groups at baseline. 
 
Static measures of beta-cell function 
SITA significantly improved fasting measures of beta-cell function, including HOMA-B, 
MBCI, and QUICKI. By contrast, in CON, HOMA-B significantly decreased and MBCI and 
QUICKI did not change (Table 2.1). The between-treatment differences in static measures of 
beta-cell function were statistically significant for HOMA-B, MBCI, and QUICKI (Table 
2.2). 
 
Changes in other measures of glycemic control 
In CON, fasting glucose was significantly increased after 12 weeks (Table 2.1). Glucose after 
120 and 180 minutes increased in CON at the end of the study, whereas glucose at 180 
minutes decreased in SITA, yet the within- and between-treatment differences were not 
statistically significant (Tables 2.1 and 2.2).  
Fasting insulin and C-peptide increased significantly in SITA and did not change significantly 
in CON (Table 2.1). The between-treatment differences for both parameters were statistically 
significant (Table 2.2). 
Due to significant increases in fasting insulin, HOMA-IR significantly increased and IAI 
significantly decreased in SITA (Table 2.1). The increase in HOMA-IR and decrease in IAI 
were significant when compared to CON (Table 2.2). 
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Table 2.1: Pretreatment and post treatment values of clinical parameters of PCOS patients for 
each of the treatment groups expressed as mean ± SD. 













 Age (years) 35.1 ± 6.4     34.8 ± 8.2     0.821 
 BMI (kg/m2) 37 ± 6.2 37.8 ± 5.9 0.050 36.8 ± 4.9 38 ± 5 0.008 0.650 
 
HOMA-B 141.7 ± 56.2 
187.6 ± 
69.4 
0.001 173.3 ± 60.2 136.9 ± 70.1 0.001 0.370 
 MBCI 7.9 ± 3.9 15.8 ± 8.6 0.002 8.4 ± 5.4 10.5 ± 10.1 0.507 0.964 
 QUICKI 0.35 ± 0.04 0.32 ± 0.03 0.002 0.35 ± 0.04 0.35 ± 0.04 0.591 0.856 
 Glu 0 min OGTT 
(mmol/l) 
5.2 ± 0.5 5.5 ± 0.4 0.082 4.9 ± 0.5 5.5 ± 0.9 0.009 0.072 
 Glu 30min OGTT 
(mmol/l) 
8  ± 1 8.1 ± 1.9 0.851 8.7 ± 1.6 8.3 ± 2.9 0.889 0.363 
 Glu 60min OGTT 
(mmol/l) 
7.9 ± 1.8 7.4 ± 2.4 0.167 9 ± 2.3 9.1 ± 3.4 0.937 0.201 
 Glu 120min OGTT 
(mmol/l) 
6.8 ± 1.3 7 ± 1.8 0.531 6.9 ± 1.9 7.7 ± 3 0.185 0.892 
 Insulin (mU/l) 10.8 ± 4.8 18.3 ± 8.7 0.002 13.4 ± 7.8 14.3 ± 9.6 0.506 0.555 
 C-peptide (pmol/l) 0.9 ± 0.3 1.3 ± 0.5 0.003 1 ± 0.4 1 ± 0.5 0.281 0.717 
 HOMA-IR 2.7 ± 1.3 4.5 ± 2.3 0.002 3.1 ± 2.2 3.7 ± 2.8 0.152 1.000 
 IAI 0.02 ± 0.02 0.01 ± 0.01 0.003 0.02 ± 0.01 0.02 ± 0.02 0.600 0.751 
 
Weight (kg) 101.4 ± 14 
103.5 ± 
12.7 
0.056 97.8 ± 8.3 101.2 ± 8.6 0.007 0.856 
 Waist 
circumference (cm) 
105.5 ± 12.2 
106.7 ± 
13.5 
0.061 106.8 ± 8.4 109.8 ± 9.7 0.005 0.683 
 DXA %fat 45.4 ± 6.2 45.2 ± 5.7 0.649 45.5 ± 4.7 [1] 45.8 ± 4.5 0.753 0.867 
 




728.6 ± 264.9 
[1] 








787.6 ± 286.5 
[1] 
878.2 ± 288.7 0.012 0.683 
 




151.2 ± 55 
[1] 
168 ± 54.9 0.018 0.683 
 GLP-1 (pM) 4.9 ± 1.8 5.2 ± 2.3 0.281 5.4 ± 3.5 [1] 4.8 ± 2.8 [1] 0.016 0.456 
 
GIP (pg/ml) 58.8 ± 24.3 63.1 ± 38.6 0.683 
66.8 ± 35.8 
[2] 
54 ± 38.9 [1] 0.059 0.721 
 Free testosterone 
(pmol/l) 
4.6 ± 2.8 4.7 ± 2.1 0.753 2.9 ± 1.7 6.8 ± 3.7 0.011 0.108 
 Total testosterone 
(nmol/l) 
1.7 ± 1.8 1.7 ± 1.8 0.449 1.2 ± 0.5 1.5 ± 0.8 0.012 0.892 
 Androstenedione 
(nmol/l) 
4.1 ± 1.5 4.5 ± 1.8 0.394 4.8 ± 2.6 4.9 ± 1.9 0.944 0.586 
 DHEAS (μmol/l) 5.8 ± 2.9 5.8 ± 3.3 0.842 5.6 ± 2.8 6 ± 2.9 0.278 0.856 
 SHBG (nmol/l) 29.1 ± 25.3 22.5 ± 7.9 0.362 62.5 ± 86.3 54.3 ± 61 [1] 0.422 0.316 
 Number of periods 
in 3 months 
2.5 ± 0.7 2.3 ± 0.9 0.414 2.8 ± 0.4  2.7 ± 0.7 0.705 0.316  
Abbreviations: BMI, body mass index; HOMA-B, homeostasis model assessment for beta-cell function; MBCI, modified 
beta-cell function index; QUICKI, quantitative insulin sensitivity check index; Glu, glucose; OGTT, oral glucose tolerance 
test; HOMA-IR, homeostasis model assessment of insulin resistance; IAI insulin action index; DXA Dual Energy X-ray 
Absorptiometer; VAT visceral adipose tissue; GLP-1 glucagon-like peptide-1; GIP glucose-dependent insulinotropic 
peptide; DHEAS dehydroepiandrosterone sulphate SHBG, sex hormone-binding globulin. 





Table 2.2: Comparison of absolute change in clinical parameters of PCOS patients among 
different treatment groups compared with nonparametric Mann-Whitney test. 
 
SITAGLIPTIN LIFESTYLE p 
Characteristic Absolute change (mean ± SD) Absolute change (mean ± SD)   
BMI (kg/m2) 0.8 ± 1.4 1.3 ± 1.7 0.751 
HOMA-B 45.9 ± 35.8 -94.8 ± 83.7 0.000 
MBCI 7.9 ± 7 2.1 ± 7 0.010 
QUICKI -0.03 ± 0.03 0 ± 0.04 0.025 
Glu 0 min OGTT (mmol/l) 0.3 ± 0.6 0.7 ± 0.9 0.156 
Glu 30 min OGTT (mmol/l) 0.1 ± 1.7 -0.4 ± 2.6 1.000 
Glu 60 min OGTT (mmol/l) -0.5 ± 1.2 0.1 ± 2 0.555 
Glu 120 min OGTT (mmol/l) 0.2 ± 0.9 0.8 ± 1.8 0.496 
Insulin (mU/l) 7.5 ± 6.7 0.9 ± 3.5 0.005 
C-peptide (pmol/l) 0.4 ± 0.4 0.1 ± 0.2 0.017 
HOMA-IR 1.8 ± 1.7 0.6 ± 1.3 0.046 
IAI -0.01 ± 0.01 0 ± 0.01 0.013 
Weight (kg) 2.1 ± 3.9 3.4 ± 4.5 0.717 
Waist circumference (cm) 1.2 ± 2.7 3.0 ±2.5 0.108 
DXA %fat -0.2 ± 1.5 -0.2 ± 0.9 [1] 0.829 
VAT mass (g) 23.6 ± 108.8 54 ± 62.3 [1] 0.139 
VAT volume (cm3) 25.5 ± 117.8 61.2 ± 67.6 [1] 0.126 
VAT area (cm2) 4.9 ± 22.5 11.2 ± 12.9 [1] 0.126 
GLP-1 (pM) 0.3 ± 0.9 -0.6 ± 0.9 [1] 0.012 
GIP (pg/ml) 4.3 ± 40.1 -22.1 ± 40.1 [2] 0.077 
Free testosterone (pmol/l) 0 ± 2.7 3.9 ± 4.2 0.022 
Total testosterone (nmol/l) 0 ± 0.4 0.3 ± 0.7 0.274 





Glucose tolerance state as assessed by OGTT 
The conversion from normal glucose tolerance to IGT or T2D was prevented in SITA. Three 
subjects had IGT before and after the study, and none had T2D. In CON, 4 women had IGT at 
the beginning; none had T2D. After 12 weeks, IGT was observed in 2 and T2D in 3 subjects 
in CON. 
 
Measures of obesity 
After metformin withdrawal, subjects shifted to lifestyle intervention in CON regained an 
average of 3.4 ± 4.5 kg (p= .007), compared with 2.1 ± 3.9 kg weight regain in the SITA 
group (p= .06). Waist circumference and VAT mass, volume, and area as measured by DXA 
significantly increased in CON compared to statistically insignificant increases in SITA 
(Table 2.1). The between-treatment differences for measures of obesity were not statistically 
significant, but there was a tendency that sitagliptin in combination with lifestyle intervention 
was superior in preventing weight regain after metformin withdrawal when compared to 
lifestyle intervention alone (Table 2.2). 
 
DHEAS (μmol/l) 0 ± 0.8 0.4 ± 1.2 0.440 
SHBG (nmol/l) -6.6 ± 22.2 -8.5 ± 39.9 [1] 0.277 
Number of periods in 3 months -0.2 ± 0.7 -0.1 ± 0.9 0.808 
BMI, body mass index; HOMA-B, homeostasis model assessment for beta-cell function; MBCI, modified beta-cell 
function index; QUICKI, quantitative insulin sensitivity check index; Glu, glucose; OGTT, oral glucose tolerance 
test; HOMA-IR, homeostasis model assessment of insulin resistance; IAI insulin action index; DXA Dual Energy X-
ray Absorptiometer; VAT visceral adipose tissue; GLP-1 glucagon-like peptide-1; GIP glucose-dependent 
insulinotropic peptide; DHEAS dehydroepiandrosterone sulphate SHBG, sex hormone-binding globulin 




Total baseline GLP-1 and GIP concentrations increased insignificantly in SITA, whereas they 
significantly decreased in CON (Table 2.1). The between-group difference was statistically 
significant for GLP-1 (Table 2.2). 
 
Endocrine outcomes 
After metformin withdrawal and within 12 weeks of the study follow-up period, total and free 
testosterone increased significantly in CON. In SITA, no significant changes were observed in 
androgen profile at the end of the study as compared to baseline values (Table 2.1). There was 
a statistically significant difference between groups in free testosterone, SITA being superior 
to CON in preserving the androgen profile after metformin cessation (Table 2.2). 
 
Menstrual pattern 
No statistically significant changes were found, either over time or when analyzing the 
parameter separately in the intervention arm (Tables 2.1 and 2.2). 
 
Adverse events 
Reporting of all transient or intermittent adverse events and precise duration periods was 
incorporated in our study protocol. Headache was documented once in SITA. In CON, 1 
subject found it hard to adhere to the recommended lifestyle measurements and needed 






The study provide the first evidence to date that DPP-4 inhibition with sitagliptin in adjunct to 
lifestyle intervention improves beta-cell function and prevents the conversion to IGT and T2D 
in metformin-intolerant obese women with PCOS, whereas lifestyle intervention alone results 
in more deleterious effects on glucose homeostasis. In addition, sitagliptin prevented 
significant weight regain as well as increase of VAT in the present study. Concentrations of 
incretin hormones tended to increase in SITA, whereas they significantly decrease in CON. 
We also demonstrated that SITA is superior to lifestyle intervention alone in preserving 
androgen profile. 
Attempts to preserve and restore beta-cell function are important to decrease conversion to 
T2D in populations with high metabolic risk [6]. The Diabetes Prevention Program and 
several other studies showed that implementing a program that decreased body weight 
through diet and exercise reduced the incidence of T2D in patients with IGT [97]. The effect 
of lifestyle intervention on reducing the incidence of T2D is related to overall improvements 
in beta-cell function driven by its gains in insulin sensitivity [98]. Physical activity per se has 
a beneficial effect on insulin sensitivity in normal as well as insulin resistant populations 
[99,100]. It influences insulin sensitivity trough decreased IR and beta-cell load accompanied 
by weight reduction and through direct influence on glucose transporter type 4 and muscle 
uptake of glucose [99,101]. Beneficial effects of physical activity on insulin sensitivity 
indexes were also demonstrated in patients with PCOS [102]. However, metformin-intolerant 
obese PCOS patients are not expected to adequately respond to lifestyle modification after 
metformin withdrawal, since they had been unsuccessful even before they had been assigned 
to metformin.  
Study demonstrated that lifestyle intervention in women that had been withdrawn from 
metformin due to its intolerance resulted in worsening of beta-cell function and in a tendency 
toward increasing IR, mainly driven by a significant increase in fasting glucose levels. We 




By contrast, significant improvement in beta-cell function when metformin-intolerant obese 
women with PCOS were switched to the DPP-4 inhibitor sitagliptin in adjunct to lifestyle 
intervention was observed. Unexpectedly, as oppose to insignificant increases in controls, IR 
as assessed by HOMA-IR in sitagliptin patients increased significantly. The increase in both 
arms was most probably related to metformin withdrawal and weight gain. Since DPP-4 
inhibitors do not increase IR, the more pronounced increase in HOMA-IR with sitagliptin 
when compared to controls does not have a mechanistically well-suited explanation. It could 
be related to the discussed limitations of the study, including small sample number and the 
chosen static models for assessing IR. Importantly, the beneficial impact of sitagliptin in the 
study was proven in other clinically relevant measures of glucose homeostasis. Rapid 
deterioration of glucose homeostasis was prevented with sitagliptin. Beneficial observations 
were in line with the present evidence suggesting that DPP-4 inhibitors improve beta-cell 
function in humans based on both static and dynamic parameters [91,103]. 
Furthermore, significantly differential effects of the two interventions regarding basal levels 
of incretin hormones were demonstrated. Total fasting GLP-1 and GIP concentrations 
insignificantly increase in SITA, whereas they significantly decreased in CON from baseline 
to the study end. The observations were consistent with the present evidence. It was 
demonstrated before that metformin could increase GIP and GLP-1 by increasing GLP-1 
biosynthesis and secretion and also by inhibiting GLP-1 degradation by inhibiting DPP-4 
[24]. Therefore, it was expected that both incretin hormones would significantly decrease in 
CON after metformin withdrawal and due to weight regain in the CON group. On the other 
hand, it was expected that sitagliptin would further increase fasting levels of incretins after 
metformin cessation, since it was demonstrated before that DPP-4 inhibition increases not 
only prandial but also fasting levels of GLP-1 and results in an overall increase in GLP-1 
levels with maintenance of circadian rhythm throughout the day [44]. 
In addition to beneficial effects on beta-cell function, glucose tolerance state, and levels of 
incretin hormones, sitagliptin also assisted with maintenance of body weight after metformin 
withdrawal, whereas a shift to lifestyle intervention alone after metformin withdrawal 
surprisingly resulted in significant weight regain, in particular due to increase in visceral 
adiposity. The observations imply that metformin had provided a favorable weight-neutral 
homeostasis that could be related to its demonstrated stimulatory effect on GLP-1 [24,104-
107]. Similarly, it is well established that DPP-4 inhibitors assist in favorable weight 
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maintenance [53]. A potential mechanism regarding the favorable weight neutrality of DPP-4 
inhibitors includes moderately delayed gastric emptying via enhancement of the GLP-1 axis, 
[61] inhibitory effects on fat absorption from the gut, and promotion of lipolysis in adipose 
tissue in the postprandial state, in conjunction with increased fatty acid oxidation in skeletal 
muscle [108]. 
Furthermore, SITA was superior to CON in preserving the androgen profile after metformin 
cessation, whereas testosterone increased in controls. The study was not designed to clarify 
whether this effect is coincidental or associated with differential effects of the two 
interventions on glucose homeostasis, body weight, and body composition. The known effect 
of metformin on androgen production has been controversial. Some have assigned the 
improvement in androgen profile to the reduction of IR. It may also be argued that metformin 
effects on androgens could be a byproduct of ovulation resumption. In vitro studies 
demonstrated that metformin inhibits androgen production by theca cells. It has also been 
suggested that metformin reduces pituitary luteinizing hormone and increases the production 
of SHBG [109]. 
The changes in menstrual frequency in both groups were not statistically significant, most 
probably due to the short duration of the study. 
The results of the study are subject to several limitations. An assessment of the impact of 
sitagliptin in adjunct to lifestyle intervention on improved beta-cell function and on the 
conversion to IGT and T2D is limited due to the short observational period. However, 
significantly differential effects between the arms observed even in that short follow-up 
period highlight the potential role of sitagliptin in adjunct to lifestyle intervention in 
metformin-intolerant women with PCOS. Furthermore, merely static measures of beta-cell 
function and IR were performed, while dynamic measures were not addressed. However, any 
tests performed for estimating beta-cell function and IR have limitations and should be 
regarded as mere surrogate estimates. In the study the parameters from the equation that 
mainly drove the change in HOMA indexes were exposed to highlight the differences 
between two arms not being obvious from the results of the changes in composite 
calculations. An important add on value to the mere estimation of beta-cell function was, that 
the improvement of beta-cell function in the context of other measures of glucose homeostasis 
















DPP-4 INHIBITOR SITAGLIPTIN PREVENTED 
WEIGHT REGAIN IN OBESE WOMEN WITH PCOS 









The most reasonable duration of weight management with liraglutide is not yet defined. 
Longitudinal observations reported that maximum rates of weight loss were achieved in the 
initial 20 week treatment period with a weight maintenance and even tendency toward weight 
gain beyond 36 week [47,110]. This might be due to the development of treatment resistance, 
most apparent after 36 weeks from initiation [111]. Integrating behavioral empowerment 
alongside with limited in-treatment period with GLP-1 analogues might be a rational cost 
benefit approach in the clinical practice. After treatment withdrawal, weight loss induced with 
liraglutide is often non-sustainable [57]. The clinical strategy to prevent the rebound of weight 
gain in subjects that have been withdrawn from liraglutide is not yet elucidated. 
As opposed to pharmacological GLP-1 agonism, the physiological role of endogenous GLP-1 
in the modulation of food intake is less clearly established [112]. The enhancement of 
endogenous incretin hormones could be achieved with DPP-4 inhibitors which are generally 
weight neutral, although modest weight reduction has been seen in some clinical trials, 
particularly when DPP-4 inhibitors are used in combination with metformin [58,59]. 
A study with rodents reported that DPP-4 inhibitor linagliptin prevented weight regain in 
animals previously treated with GLP-1 receptor agonist. Although presently untested in 
humans, this raises the intriguing possibility of using GLP-1 agonism to induce weight loss, 
followed by enhancement of endogenous incretin axis via DPP-4 inhibition for weight 
maintenance after stopping liraglutide. 
This study is the first investigation into the potential prevention of weight regain in obese 
patients after cessation of anti-obesity treatment with liraglutide with the enhancement of 
endogenous incretin hormones with DPP-4 inhibition. The aim was to evaluate whether DPP-
4 inhibitor sitagliptin in adjunct with metformin prevent body weight regain more effectively 




SUBJECTS AND METHODS 
 
 
Study design and participants 
The study consists of a 12-week prospective randomized open-label design conducted with 24 
obese women with PCOS (aged 34.3±6.8 years, BMI 36.3±5.2 kg/m2, mean ± SD) diagnosed 
by ASRM-ESHRE Rotterdam criteria that had been pre-treated with liraglutide 3.0 mg for 12 
weeks due to weight management. After liraglutide cessation they were switched to 
metformin (MET) 1000 mg twicw a day alone (N=12) or combined treatment (COMBO) with 
metformin 1000 mg twice a day and sitagliptin 100 mg once a day (N=12). The primary 
outcome was change in anthropometric measures of obesity. The secondary outcomes were 
changes in hormonal and metabolic parameters and assessment of changes in eating behavior. 
All subjects had type A phenotype of PCOS including concomitant presence of a) 
hyperandrogenemia on either the biochemical or the clinical level, b) menses abnormalities 
and c) PCO morphology. They were eligible for enrollment if they were aged 18 years to 
menopause and obese (body mass index: BMI ≥ 30). Exclusion criteria were significant 
cardiovascular, kidney or hepatic disease, personal or family history of medullary thyroid 
carcinoma, known history of gallbladder disease or pancreatitis. They have no concomitant 
treatment. Pregnancy was excluded by measuring β-human chorionic gonadotropin. Women 
were advised to strictly use barrier contraception.  
Lifestyle intervention was reinforced after liraglutide cessation in both groups. Subjects 
received group counseling regarding lifestyle Intervention. Reducing diet of 500-800 kcal/day 
reduction made up of 50% carbohydrates, 20% proteins and 30% of fat with increased 
consumption of fiber, whole grains, cereals, fruits and vegetables along with at least 30 min of 
moderate intensity physical activity daily was promoted. 
Post randomization and at study endpoint all patients underwent standard anthropometric 
measurements: height, weight, waist circumference. A fasting blood sample was drawn for 
determination of androstenedione, total and free testosterone (T), sex hormone binding 
globulin (SHBG) and lipids followed by a 2-h OGTT. Blood samples for glucose and insulin 
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were drawn at 0 and 120 min of OGTT. In addition, eating behavior was assessed by Three-
Factor Eating Questionnaire (TFEQ-R18) at baseline and after 12 weeks [113]. Safety clinical 
assessment was performed at the beginning and at the end of the treatment period. The study 
protocol is shown in Scheme 3. 
 





Glucose levels were determined using a standard glucose oxidase method (Beckman Coulter 
Glucose Analyzer, Beckman Coulter Inc CA, USA). Insulin was determined by 
immunoradiometric assay (Biosource Europe S.A., Nivelles, Belgium). Lipids were 
determined using Adiva 1800, Siemens analyzer. LH and FSH were determined using an 
immunometric assay (Diagnostic Products Corporation, LA). Androstenedione was measured 
by specific double antibody RIA using 125 I-labeled hormones (Diagnostic Systems 
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Laboratories, Webster, Tx). Total and free testosterone levels were measured by coated tube 
RIA (DiaSorin, S. p. A, Salluggia, Italy and Diagnostic Products Corporation, LA, 
respectively). SHBG was determined with a chemiluminescent immunoassay (Immulite 2000 
Analyzer, Siemens Healthcare, Erlangen, Germany). Intra-assay variations ranged from 1.6 to 
6.3%, and inter-assay variations ranged from 5.8 to 9.6 % for the applied methods. Pre- and 
post-treatment samples from each patient were assayed in the same assay run. 
 
Calculations 
Body mass index (BMI) was calculated as the weight in kilograms divided by square of height 
in meters. 
Homeostasis model assessment (HOMA-IR) calculation was applied as a measure for IR. It 
was evaluated as the product of the OGTT glucose (mmol/L) and insulin (U/mL) 
concentration at time 0 divided by 22.5 [72]. 
 
Assessment of eating behavior 
Eating behaviour was assessed by a Slovenian translation of Three-Factor Eating 
Questionnaire (TFEQ-R18) [113]. The instrument is a shortened and revised version of the 
original 51-item TFEQ [114]. The translation of the Slovenian version had been back-
translated by a native English speaker and evaluated as required. The questionnaire measures 
3 different aspects of eating behaviour: cognitive restraint (CR) referring to conscious 
restriction of food intake in order to control body weight or to promote weight loss, 
uncontrolled eating (UE) referring to tendency to eat more than usual due to a loss of control 
over intake accompanied by subjective feelings of hunger, and emotional eating (EE) 
referring to inability to resist emotional cues. The TFEQ-R18 consists of 18 items on a 4-
point response scale (definitely true/mostly true/mostly false/definitely false). Responses to 
each of the 18 items are given a score between 1 and 4 and item scores are summed up into 
scale scores for CR, UE, and EE [113,114]. The raw scale scores are transformed to a 0–100 
scale [((raw score − lowest possible raw score)/possible raw score range) × 100] and the 
commonly used “half-scale” method is utilized to compensate for missing data on some items. 




The study was approved by a Slovene National Medical Ethics Committee and conducted in 
accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Written 
informed consent was obtained from all patients before participation. The study is registered 
on www.ClinicalTrials.gov as NCT02941445.  
 
Statistical analysis 
Mean values with standard deviations were used to describe continuous variables. To compare 
pretreatment and post-treatment values of continuous variables, we used nonparametric 
Wilcoxon signed-rank test for related samples, while nonparametric Mann-Whitney test was 
used to compare the change of clinical parameters among different treatment groups. Two 
tailed p values of <0.05 were considered statistically significant. All statistical analyses were 








24 patients completed the study: 12 on MET and 12 on COMBO. Baseline characteristics of 
the patients are provided in Table 3.1. There were no statistically significant differences 
between both groups at baseline. 
 
Measures of obesity 
Before randomization the average weight loss induced with 12-week treatment with 
liraglutide 3 mg was 5.1±3.6 kg. Weight regain in 12 weeks after liraglutide cessation did not 
correlate with weight loss achieved with liraglutide before randomization (Spearman 
rho=0.063, p=0.770, Figure 3.1). 
The mean pre- and post-treatment measures of obesity are presented in Table 3.1. Subjects 
treated with MET alone regain on average 4.7 ± 2.7 kg (p=0.002) compared with a 0.9 ± 2.5 
kg weight regain in COMBO group (p=0.147). BMI increased for 1.7 ± 0.9 kg/m2 in MET 
arm (p=0.002) compared to statistically insignificant increase for 0.3 ± 0.8 kg/m2 in COMBO. 
12 weeks after liraglutide withdrawn MET group regain on average 4.5± 2.5% of body weight 
compared to 0.8±2.6% in COMBO. Waist circumference increase for 1.9± 5.8 cm (p=0.17) in 
MET and decrease for 2.0±6.3 cm (p=0.11) in COMBO. The between treatment differences 
were statistically significant for weight change (p<0.001), percentage of weight change 
(p<0.001) and BMI change (p<0.001) (Table 3.1). 
 
Hormonal and metabolic parameters 
There were no between treatment statistical differences in hormonal and metabolic 
parameters. Despite an average weight regain in MET they did not significantly worsen in 
either group (Table 3.1). 
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Table 3.1: Clinical characteristics of patients treated with metformin (MET, N=12) or 
metformin + sitagliptine (COMBO, N=12) and comparison of change of clinical 
characteristics during treatment between treatment groups. 













pa MET COMBO pb 
Weight (kg) 101.2±12.1 105.9±13.
7 
0.002 100.4±12.9 101.4±14.0 0.147 4.7±2.7 0.9±2.5 0.001 






0.168 105.3±12.7 103.3±12.5 0.307 1.9±5.8 -2.0±6.3 0.114 
LH (IU/l) 6.4±4.3 5.8±2.7 
[1] 
0.799 7.9±8.1 8.8±14.5 0.666 -0.7±4.5 [2] 0.9±7.3 0.974 
FSH (IU/l) 3.6±1.6 4.9±2.0 
[1] 
0.017 5.5±2.3 5.2±3.0 0.695 1.8±1.8 [2] -0.3±2.4 0.036 
Androstenedio
ne (nmol/l) 








10.6±2.7 8.6±4.3 0.061 10.9±5.6 10.0±4.6 0.666 -2.0±3.7 -0.8±5.5 0.242 
SHBG (nmol/l) 45±6.9 40.6±48.0 0.248 54.3±96.8 47.3±68.6 0.656 -4.4±13.3 -7.1±29.4 0.443 





0.656 5.1±0.4 4.7±0.4 [2] 0.065 -0.2±0.9 [1] -0.2±0.3 
[2] 
0.557 
Glu 120 min 
OGTT 
(mmol/l) 
5.1±1.4 [1] 6.5±2.3 
[1] 




Abbreviations: BMI, body mass index; LH, luteinizing hormone; FSH, follicle-stimulating 
hormone; SHBG, sex hormone-binding globulin; Glu, glucose; OGTT, oral glucose tolerance 
test; HOMA-IR, homeostasis model assessment of insulin resistance; HDL, high-density 
lipoprotein; LDL, low-density lipoprotein; SD, standard deviation; TAG, triacylglycerides 
Notes: For each parameter, missing data are presented in brackets [] 
aComparison of values before and after treatment for each treatment group.  
bComparison of change of clinical characteristics during treatment between treatment groups. 












0.594 65.1±27.8 60.9±44.4 0.480 10.4±35.5 
[1] 
-4.1±45.9 0.413 
HOMA-IR 6.1±7.1 2.9±1.8 
[2] 





4.8±1.0 4.9±1.1 0.439 4.9±1.0 4.9±1.1 0.371 0.1±0.4 0.1±0.4 0.932 
HDL (mmol/l) 1.3±0.2 1.4±0.2 0.348 1.2±0.2 1.3±0.2 0.020 0.0±0.2 0.1±0.1 0.478 
LDL (mmol/l) 2.9±0.9 2.9±0.9 0.134 3.0±0.9 3.1±0.8 0.878 0.1±0.2 0.0±0.3 0.443 
TAG (mmol/l) 1.3±0.5 1.4±0.5 0.355 1.5±0.7 1.6±0.8 0.319 0.2±0.4 0.1±0.3 0.977 
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Figure 3.1: Weight change induced with liraglutide treatment before randomization did not 
correlate with weight change on MET (blue circles) or COMBO treatment (green circles) 
(Spearman rho=0.063, p=0.770). 
 
 
Assessment of eating behavior 
The ability to resist emotional cues as demonstrated by a decrease of EE scores by TFEQ-R18 
was significantly greater in COMBO as compared to MET (-9.8±14.9 vs. -3.4±14.1 scores, 
respectively, p=0.04). However, the statistically significant between treatment differences in 
the CR (-0.4±16.5 in MET vs. -0.4±16.5 in COMBO) and UE (-3.3±11.8 in MET vs. -
0.4±16.5 scores in COMBO) were not detected. 
 
Adverse events 
The most commonly reported adverse event was diarrhea (5/12 in MET and 6/12 in 
COMBO). In COMBO women reported nausea (3/12) and pain in lower abdomen (2/12). In 
MET 2/12 reported nausea and 1/12 vomiting. No adverse reactions leading to withdrawal in 






The study provided the first evidence to date that DPP-4 inhibition prevented weight regain 
after liraglutide 3.0 mg cessation. Within a 12-week follow up period DPP-4 inhibitor 
sitagliptin in adjunct to metformin resulted in weight maintenance, whereas a switch to 
metformin alone resulted in a significant weight regain. In addition, it was demonstrated that 
the ability to resist emotional eating was greater in COMBO as compared to MET. 
After liraglutide 3.0 mg cessation no further weight loss was observed in either group. A 
switch to metformin led to significant weight gain of 4.55%. Weight regain did not correlate 
with weight loss achieved with liraglutide 3.0 mg. Results in MET group were comparable to 
the large double-blind, placebo-controlled SCALE Diabetes Trial, which assessed efficacy 
and safety after liraglutide cessation [57]. They reported that after liraglutide cessation, 
weight regain was observed, yet the weight loss from baseline still remained greater in 
liraglutide arm (4.66%) when compared to placebo arm (2.50%) [57]. 
By contrast, sitagliptin 100 mg once daily in adjunct to metformin prevented a significant 
weight regain. The results were in line with an animal model using DPP-4 inhibitor linagliptin 
after short acting GLP-1 analogue exenatide [115]. Linagliptin significantly delayed weight 
gain after exenatide cessation [115]. One explanation provided by the authors was that the 
effect of DPP-4 inhibitors on body weight is dependent upon weight status, depending of 
whether an animal is in weight stable homeostasis or it is actively putting on weight. 
Furthermore, they showed that DPP-4 inhibition modulated food preference of the animals 
during treatment withdrawal [115]. 
In humans, some potential mechanisms for favorable weight neutrality of DPP-4 inhibitors, as 
opposed to the majority of other weight regaining non-incretin antidiabetic agents, had been 
proposed. DPP-4 inhibition with sitagliptin or vildagliptin moderately delayed gastric 
emptying [61]. As gastric emptying has impact on body weight and on self-reported feelings 
of sitation [116], delayed gastric emptying caused via DPP-4 inhibition could potentially 
reverses the negative reinforcement of hyperphagia. Furthermore, DPP-4 inhibition may have 
an inhibitory effect on fat absorbtion from the gut and promotion of lipolysis in adipose tissue 
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in the postprandial state, in conjunction with increased fatty acid oxidation in skeletal muscle 
[108]. 
In COMBO group we detected a reducing effect of sitagliptin in adjunct to metformin on 
emotional eating that had not been observed in metformin arm. Resistance to emotional eating 
demonstrated in COMBO could be attributable to delayed gastric emptying that had been 
previously observed with sitagliptin [61]. A relationship between the ability to resist 
emotional cues and gastric emptying had been well defined [116]. Several studies suggested 
that delayed postprandial onset of satiation and less fullness in individuals with morbid 
obesity is related to relatively rapid gastric emptying compared to normal weight controls 
[117-122]. 
The results of the study are subject to several limitations. It was designed essentially as a 
proof of concept, pilot study. Short period and small sample size limited the assessment of the 
impact of DPP-4 inhibition on weight maintenance. Furthermore, mechanisms responsible for 
the weight maintenance with DPP-4 inhibitors were not addressed. However, the main 
strength of this study was the first insight into the potential treatment regimen including initial 
weight loss via GLP-1 agonism subsequently replaced by a DPP-4 inhibition. We designed an 
original model of dynamic state when active weight gain after liraglutide withdrawal had been 
expected. The contribution of DPP-4 inhibition on weight maintenance was unmasked. Study 
offers the frame for potential pragmatic approach to a clinically relevant issue. Future larger 
designs of longer duration in different obesity related populations should be powered using 












SUMMARY AND CONCLUSIONS 
 
 
The dissertation consists of three self-standing studies, designed to form related unit which 
demonstrate some important new insights in the role of the impaired incrtein axis in obese 
women with PCOS and the beneficial impact of degradation inhibitor of glucagon like 
polypeptide 1 on body weight and beta-cell function in the subset of women with PCOS with 
the highest metabolic risk. 
In the first part it was shown that GLP-1 response in obese women with PCOS is significantly 
lower in the group with prediabetes than in the group with normal glucose tolerance. 
Although the sequence of cause and effect regarding relationship between glucose tolerance 
status and GLP-1 response is uncertain yet, the results indicate a new separate risk factor for 
prediabetes in PCOS independent of BMI, age and disease phenotype in particular with 
predominant visceral obesity. Impaired GLP-1 response can contribute to deregulation of 
glucose metabolism, rather than being a mere consequence of obesity and diabetes. Findings 
imply consideration about enhancement of impaired GLP-1 axis by individually tailored 
strategies based on GLP-1 receptor agonists and DPP-4 inhibitors in a subset of women with 
PCOS with the highest metabolic risk and expected fast conversion rate toward diabetes. 
In the second part we demonstrated that enhancement of endogenous incretin effect with 
DPP-4 inhibitor sitagliptin can preserve beta-cell function and delay development of impaired 
glucose homeostasis in metformin-intolerant PCOS In addition, sitagliptin also assisted with 
maintenance of body weight after metformin withdrawal. Although the small sample size and 
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short duration limited the generalizability of the results, the study had provided several 
evidences implying that DPP-4 inhibitors as an add on to lifestyle intervention might have 
beneficial effects on beta-cell function and glucose tolerance state in PCOS women with high 
metabolic risk that have failed with lifestyle intervention and are metformin-intolerant. Future 
larger designs of longer duration should be powered using our preliminary results. 
In the third part the influence of DPP-4 inhibitor on body weight after cessation of anti-
obesity treatment with liraglutide in obese women with PCOS had been investigated. It was 
demonstrated that combined treatment of DPP-4 inhibitor sitagliptin and metformin resulted 
in prevention of weight regain after liraglutide withdrawal. This potential sequencial 
treatment concept might be particularly useful in patients who became intolerant, develop 
treatment resistance or decide to stop the anti-obesity treatment with liraglutide. Further 
research is necessary to fully understand the cross talks between effects of peripheral signals 















Sindrom policističnih ovarijev (PCOS) je endokrina motnja, ki je prisotna pri 15-20% žensk v 
rodnem obdobju (1). Za sindrom je značilno pojavljanje heterogenih reproduktivnih, 
presnovnih in androgenizirajočih simptomov in znakov, ki se lahko kažejo z različnimi 
fenotipi. Na izraženost in stopnjo simptomov in znakov sindroma močno vpliva debelost, ki je 
prisotna pri 40-80% bolnic s PCOS [2,3]. S prekomerno telesno maso se povečuje inzulinska 
rezistenca (IR) [4], ki skupaj z oslabljeno inzulinsko senzitivnostjo in beta-celično funkcijo 
pri debelih bolnicah s PCOS vodi v pospešen razvoj prediabetesa in sladkorne bolezni tipa 2. 
[6] Motena toleranca za glukozo in sladkorna bolezen tipa 2 sta pri teh bolnicah prisotni v 30-
45% že v reproduktivnem obdobju [5]. Debelost poslabšuje tudi izraženost in stopnjo 
nepresnovnih zapletov PCOS, saj IR poviša nivo in biološko učinkovitost androgenov, ki so 
ključni v patogenezi sindroma. Redukcija telesne mase je zato pri debelih bolnicah s PCOS 
ključnega pomena. Že 5-10% znižanje telesne mase občutno izboljša IR in poveča število 
ovulacij ter zmanjša presnovno ogroženost [8]. 
Pri nižanju in vzdrževanju telesne mase in energetskega ravnovesja je bistvenega pomena 
uravnavanje apetita in energetskega vnosa, ki ga zagotavlja komunikacija med odgovornimi 
centri v osrednjem živčevju in perifernimi signali, vključno s tistimi iz gastrointestinalnega 
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trakta. Del slednjih so inkretinski hormoni, ki so poleg vpletenosti v energetsko ravnovesje 
vključeni tudi v homeostazo glukoze [9,12]. Razvoj motene glukozne homeostaze je pri 
PCOS tesno povezan z debelostjo, starostjo in fenotipom bolezni. Morebitna neodvisna vloga 
oslabljenega inkretinskega odgovora pri razvoju prediabetesa in SB pri ženskah s PCOS in 
debelostjo zaenkrat ni znana [22-28]. 
Pri ženskah s PCOS in debelostjo sta sprememba življenjskega sloga in metformin terapiji 
prvega izbora [36]. Metformin zmanjšuje inzulinsko rezistenco in s tem zmanjšuje verjetnost 
napredovanja v prediabetes in SB2, medtem ko na ohranitev beta-celične funkcije nima vpliva 
[7]. Ugodno vpliva tudi na ureditev menstrualnih ciklusov in izboljšanje ovulatornosti [37-
39]. Zaradi pridruženih gastrointestinalnih težav ga 5-10% žensk ne prenaša. Alternativna 
farmakološka strategija pri bolnicah s PCOS, ki metformina ne prenašajo zaenkrat ni na voljo 
[43]. 
Zaviralci dipeptidil peptidaze-4 (zaviralci DPP-4) zavirajo encim DPP-4, ki sicer inaktivira 
inkretinske hormone. Spodbujajo podaljšan endogeni inkretinski učinek in vodijo k 
izboljšanju presnovne urejenosti ter s tem k zmanjšanju presnovne ogroženosti [44]. Zaviralci 
DPP-4 bi lahko predstavljali alternativno farmakološko intervencijo pri bolnicah s PCOS in 
visoko presnovno ogroženostjo, kadar zdravljenje z metforminom ni možno.  
Uporaba agonista receptorjev glukagonu podobnega peptida 1 (GLP-1 RA) liraglutida je 
ustaljena terapija za zdravljenje debelosti [47]. Ugodne učinke kratkotrajnih intervencij z 
liraglutidom, v monoterapiji ali v kombinaciji z metforminom, na telesno maso so opazili tudi 
pri bolnicah s sindromom policističnih jajčnikov [50-54]. Klinične izkušnje pri debelih 
bolnikih s sladkorno boleznijo kažejo, da prenehanje terapije z GLP-1 RA praviloma povzroči 
ponovno pridobivanje telesne mase [57]. Klinična strategija za preprečevanje ponovnega 
povečanja telesne mase pri osebah, kjer je bila terapija z GLP-1 RA ukinjena še ni 
oblikovana. 
Zaviralci DPP-4 na splošno nimajo redukcijskega učinka na telesno maso, čeprav je bil v 
nekaterih kliničnih raziskavah potrjen blag upad le-te, zlasti, kadar so bili DPP-4 inhibitorji 
uporabljeni v kombinaciji z metforminom [58,59]. Že zgolj dejstvo, da inhibicija DPP-4 ni 
povezana s povečanjem telesne mase, ki običajno spremlja izboljšanje urejenosti glikemije pri 
bolnikih s sladkorno boleznijo tipa 2, kaže, da DPP-4 inhibitorji v tem pogledu verjetno niso 
popolnoma nevtralni [60]. Glede na izsledke na živalskih modelih, DPP-4 inhibitorji s 
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podaljšanjem in ojačanjem delovanja endogenih inkretinov preprečijo ponoven porast telesne 
mase po ukinitvi zdravljenja z liraglutidom [115]. Na ljudeh vpliv nadaljevanja zdravljenja z 
DPP-4 zaviralci po zaključenem zdravljenju z liraglutidom na vzdrževanje telesne mase še ni 
bil preučevan.  
V disertaciji smo z zaokroženo celoto treh raziskav želeli preučiti inkretinski sistem kot 
potencialno novo prijemališče zdravljenja pri določenih podskupinah ženskah z debelostjo in 
s sindromom policističnih jajčnikov. V prvem delu smo primerjali odziv GLP-1 na 
obremenitev z glukozo, pri debelih bolnicah s PCOS in normalno toleranco za glukozo in 
debelih bolnicah s PCOS in prediabetesom. V drugem delu smo ocenili vpliv zaviralca DPP-4 
sitagliptina na funkcijo beta-celic pri bolnicah s PCOS, ki ne prenašajo metformina. V tretjem 
delu smo preverili vpliv  sitagliptina na vzdrževanje telesne mase pri bolnicah s PCOS po 
prenehanju terapije z liraglutidom. 
 
Zasnova raziskav, metode  
V prvem delu smo v presečni raziskavi preverili hipotezo, da je inkretinski učinek po 
obremenitvi z glukozo pri debelih ženskah s PCOS in moteno glukozno homeostazo oslabljen 
v primerjavi z debelimi ženskami s PCOS in normalno glukozno homeostazo. V raziskavo 
smo vključili 26 debelih preiskovank s PCOS fenotipa A, od tega 13 z normalno glukozno 
toleranco (NGT) in 13 s prediabetesom (PREDIA). Prediabetes je bil opredeljen na podlagi 
kriterijev Ameriškega diabetološkega združenja (ADA kriteriji) kot motena bazalna glikemija 
(MBG), motena toleranca za glukozo (MTG) ali oboje [69]. Preiskovanke se niso razlikovale 
v starosti in indeksu telesne mase (ITM). Vse preiskovanke so opravile 3-urni oralni glukozno 
tolerančni test (OGTT), med katerim so bili odvzeti vzorci krvi za določitev serumske 
glukoze, C-peptida, inzulina, totalnega GLP-1 in GIP. Za oceno beta-celične funkcije in 
insulinske rezistence smo uporabili statične in dinamične modelne indekse: HOMA-B, MBCI, 
QUICKI in OGIS za oceno beta-celične funckije in HOMA-B in IAI za oceno inzulinske 
rezistence. Vse preiskovanke so opravile merjenje sestave celega telesa s pomočjo 
rentgenskega absorptiometra Hologic Dual Energy (DXA). Parametre obeh skupin smo nato 
primerjali med seboj. 
V drugem delu je bila izvedena 12-tedenska prospektivna randomizirana odprta raziskava s 30 
preiskovankami s PCOS in debelostjo, ki ne prenašajo metformina. Intoleranca metformina je 
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bila opredeljena s prisotnostjo nevzdržnih gastrointestinalnih stranskih učinkov, ki so se 
pojavili z metforminom pred randomizacijo. Po ukinitvi metformina so bile preiskovanke 
randomizirane v skupino, ki je prejemala sitagliptin 100mg/dan (SITA), in kontrolno skupino 
(CON), ki ni prejemala nobene farmakološke terapije, kar je skladno z dosedanjo klinično 
prakso. Preiskovanke obeh skupin so opravile motivacijsko izobraževanje glede redukcijske 
diete in ustrezne telesne aktivnosti z individualnim svetovanjem. Na začetku in koncu 
raziskave so opravile 2-urni OGTT med katerim so bili odvzeti vzorci krvi za določitev 
serumske glukoze, C-peptida in inzulina. Beta-celična funkcija in inzulinska rezistenca sta bili 
določeni na podlagi statičnih modelnih indeksov: HOMA-B, MBCI in QUICKI za beta-
celično funkcijo in HOMA-IR in IAI za oceno inzulinske rezistence. Na začetku in koncu 
raziskave so preiskovanke opravile antropometrične teste, merjenje sestave celega telesa s 
pomočjo rentgenskega absorptiometra Hologic Dual Energy (DXA) in biokemične teste z 
določitvijo lipidograma, hormonskega statusa in bazalne koncentracije celokupnega GLP-1 in 
GIP.  
V raziskavi smo želeli preveriti hipotezo o koristnem učinku zaviralcev DPP-4 na delovanje 
beta-celic pri neprenašalkah metformina.  
V tretjem delu smo z 12-tedensko randomizirano odprto klinično raziskavo želeli proučiti 
učinkovitost kombiniranega zdravljenja z DPP-4 inhibitorjem in metforminom na vzdrževanje 
z liraglutidom dosežene znižane telesne mase po zaključeni terapiji z liraglutidom v 
primerjavi z monoterapijo z metforminom. V raziskavo smo vključili 24 preiskovank s PCOS 
in debelostjo, ki so bile predhodno zaradi debelosti zdravljene z liraglutidom. Po ukinitvi 
liraglutida so bile randomizirane v skupino, ki je prejemala kombinirano terapijo s 
sitagliptinom 100 mg/dan in metforminom 1000 mg dvakrat dnevno (COMBO skupina) in 
skupino, ki je prejemala monoterapijo z metforminom 1000 mg dvakrat dnevno (MET 
skupina). V obeh skupinah je bil ob randomizaciji promoviran zdrav življenski slog. Po 
randomizaciji in na koncu študije so vse udeleženke opravile standardne antropometrične in 
endokrine meritve. V raziskavi smo ocenili spremembe v antropometričnih meritvah 
debelosti, določili spremembe v metabolnem in hormonskem statusu ter s trifaktorskim 





Indeks telesne mase (ITM) smo izračunali na podlagi telesne mase in telesne višine ( kg/m2). 
ITM= telesna masa (kg)/kvadrat telesne višine (m2). 
Inzulinsko rezistenco smo ocenili s pomočjo IAI indeksa (ang. Insulin action index) [70] in 
homeostaznega modela ocene inzulinske rezistence (ang. homeostasis model assessment of 
insulin resistance HOMA-IR) [72], ki smo ju izračunali po formulah: IAI = 1 /(I0×G0) in 
HOMA-IR=(I0 x G0) / 22,5 kjer je I0 (mE/L)= vrednost insulina na tešče in G0 (mmol/L)= 
koncentracija glukoze na tešče.  
Za oceno beta-celične funkcije smo uporabili parametre:  homeostazni model ocene beta-
celične funkcije (ang. homeostasis model assessment for beta-cell function HOMA- β), 
preoblikovan β-celični funkcijski indeks (ang.  modified β-cell function index MBCI) [70] in 
kvantitativni indeks insulinske senzitivnosti (ang. quantitative insulin sensitivity check index 
QUICKI) [71], ki smo jih izračunali po formulah HOMA-β = 20× I0/(G0-3.5); MBCI = 
I0×G0/(G120+G60-7) in QUICKI = 1/[log(I0) + log(G0)], pri čemer je I0 (mE/L)= vrednost 
insulina na tešče in G0 (mmol/L)= koncentracija glukoze na tešče, G60 (mmol/L) = 
koncentracija glukoze v 60. min OGTT in G120 (mmol/L) = koncentracija glukoze v 120. min. 
OGTT. Indeks inzulinske senzitivnosti (ang. oral glucose insulin sensitivity index  (OGIS)) 
smo pridobili na podlagi meritev koncentracije inzulina in glukoze med 3-urnim OGTT. 
Uporabili smo internetni kalkulator dosegljiv na: http//webmet.pd.cnr.it/ogis/index.php. 
 
Rezultati 
V prvi študiji smo ugotovili, da imajo debele ženske s PCOS in prediabetesom značilno nižji 
GLP-1 odgovor po obremenitvi z glukozo (GLP-1 v 120 min 3.3±2.1 vs. 5.5±2.7 pM) v 
primerjavi z preiskovankami z normalno glukozno toleranco (P=0.014). Vrednosti GLP-1 v 
120 min, ki so bile nižje od 3,0 pM, so napovedale prediabetes (občutljivost 0,615 in 
specifičnost 0,923). Ženske s prediabetesom so imele nižji indeks občutljivosti na insulin 
(OGIS) (387 ± 69,5 v primerjavi z 326,6 ± 59,7 v NGT, P = 0,04), hkrati so imele te 
preiskovanke med OGTT višje vrednosti insulina in C-peptida s pomembno razliko pri 90 in 
120 min OGTT (P = 0,01). Kljub temu, da se skupini nista razlikovali po ITM, je bila masa, 
volumen in površina visceralne maščobe (visceral adipose tissue (VAT)) v skupini žensk s 
60 
 
prediabetesom večja v primerjavi s skupino NGT. Vrednosti GLP-1 v 120 min OGTT so bile 
negativno povezane z VAT maso (r=-0.388, p=0.05) in VAT volumnom (r=-0.390, p=0.05) 
ter pozitivno z indeksom OGIS (r= 0.424, p=0.031). Potrjena je bila tudi negativna povezava 
med razliko v odgovoru GLP-1 na glukozno obremenitev in družinsko anamnezo vsaj enega 
prvostopenjskega sorodnika s sladkorno boleznijo tipa 2 (r = -0,28 ± 0,91, p = 0,04).  
V drugi študiji smo v skupini, ki je prejemala DPP-4 zaviralec sitagliptin, ugotovili 
izboljšanje parametrov beta-celične funkcije, ki smo jo ocenjevali s homeostaznim modelom 
ocene beta-celične funkcije (HOMA-B) za 45,9 ± 35,8 (p = 0,001), s preoblikovanim 
indeksom beta-celične funkcije (MBCI) za 7,9 ± 7 (p = 0,002) in s kvantitativnim indeksom 
insulinske občutljivosti (QUICKI) za -0,03 ± 0,03 (p = 0,002). Z enakimi parametri ocenjena 
beta-celična funkcija se je v skupini CON poslabšala. Razlike med skupinama so bile 
statistično pomembne za HOMA-B (p = 0,000), MBCI (p = 0,010) in QUICKI (p = 0,025). 
Poleg poslabšanja beta-celične funkcije smo v skupini CON zaznali progresivno slabšanje 
glukozne tolerance. V tej skupini na začetku raziskave nobena od preiskovank ni imela 
sladkorne bolezni tipa 2, 4 so imele MTG, po dvanajstih tednih je bila MTG prisotna pri 2 
preiskovankah, pri treh pa se je pojavila sladkorna bolezen. Nasprotno med preiskovankami, 
ki so prejemale sitagliptin, v času študije ni bilo sprememb glede glukozne tolerance. V tej 
skupini so imele pred in po študiji moteno glukozno toleranco 3 od 15 preiskovank. 
Koristen učinek DPP-4 zaviralcev smo potrdili tudi v tretji raziskavi, kjer je v skupini 
preiskovank, ki so po ukinitvi liraglutida nadaljevale s kombinirano terapijo z DPP-4 
zaviralcem sitagliptinom in metforminom prišlo do neznačilnega manjšega porasta telesne 
mase v primerjavi s skupino, ki je po liraglutidu nadaljevala zdravljenje le z monoterapijo z 
metforminom. Preiskovanke v skupini MET so v povprečju pridobile 4,7 ± 2,7 kg (p=0,002), 
medtem ko se je telesna masa žensk v skupini COMBO povečala le za 0,9 ± 2,5 kg (p=0,147). 
ITM se je v skupini MET povečal za 1,7 ± 0,9 kg/m2 (p=0,002), v skupini COMBO za 0,3 ± 
0,8 kg/m2 (p=0,136). Preiskovanke v skupini MET so ponovno pridobile 4,5± 2,5%  telesne 
mase, medtem ko so preiskovanke v skupini COMBO, pridobile 0.8±2.6% telesne mase. Med 
skupinama smo potrdili pomembno razliko pri porastu telesne mase (p<0.001), porastu 
odstotka telesne mase (p<0.001) in porastu ITM (p<0.001). Hkrati je bila v skupini COMBO 





Oslabljen inkretinski sistem ima pomemben vpliv na presnovne zaplete pri bolnicah s PCOS 
in debelostjo. V pričujoči disertaciji smo ugotovili, da je pri bolnicah s PCOS, ki imajo 
prediabetes, inkretinski odgovor pomembno znižan in  neodvisen od ITM, starosti in fenotipa 
bolezni. Vrednosti GLP-1 po obremenitvi z glukozo pod 3,0 pM so značilne za prediabetes. 
Prikazali smo pozitivno povezavo med vrednostmi GLP-1 in beta-celično funkcijo in 
negativno povezavo odziva GLP-1 s prisotnostjo visceralnega maščevja. Naše ugotovitve 
opredeljujejo nov neodvisen dejavnik tveganja za prediabetes pri debelih PCOS, zlasti pri 
prevladujoči visceralni debelosti. 
Pri bolnicah s PCOS, ki ne prenašajo metformina smo s podaljšanjem endogenega 
inkretinskega učinka, ki smo ga dosegli s terapijo z DPP-4 zaviralci, dosegli izboljšanje 
delovanja beta-celice. Ob terapiji z DPP-4 zaviralci smo opazili tendenco upočasnitve 
progresa okvare glukozne tolerance oz. nastanek prediabetesa in sladkorne bolezni tipa 2, kar 
je najverjetneje ravno tako odraz izboljšanja delovanja beta-celice. Naši rezultati nakazujejo, 
da bi DPP-4 zaviralci lahko predstavljali alternativno možnost zdravljenja pri bolnicah s 
PCOS in debelostjo, ki ne prenašajo metformina. 
Po ukinitvi zdravljenja z GLP-1 agonistom liraglutidom smo dokazali učinkovitejše 
preprečevaje ponovnega pridobivanja telesne mase z DPP-4 zaviralci v kombinaciji z 
metforminom v primerjavi z monoterpijo z metforminom, kar je skladno z ugotovitvami na 
predhodnjih živalskih modelih [115]. Ugotovitve naše raziskave nakazujejo smiselnost 
dodajanja DPP-4 zaviralcev k terapiji z metforminom po ukinitvi zdravljenja debelosti z GLP-
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